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Multi-Functional Polymer Vesicles: Applications in Chemotherapy and
Photodynamic Therapy
Abstract
The field of drug delivery is rapidly expanding to bridge the gap between novel drugs that are created and
their effective entry into diseased tissue. In one growing area of research, synthetic polymers are being
utilized to meet these needs. The precise control over their chemistry allows polymers to be tuned to the
drug delivery application and make them attractive candidates for research. The focus of this dissertation
is to engineer responsive polymersomes for drug delivery and understand their ability to reduce drug
toxicity, increase absorption in diseased cells and tissue, and control the release of drug in vitro and in
vivo. Gemcitabine, a nucleoside analog, was encapsulated in the aqueous core of nano-polymersomes
composed of the biodegradable and biocompatible polymer PEO-PCL, and the in vitro toxicity of this novel
drug delivery construct was tested against Panc-1 cells. The polymersome formulation performed at par
with the free drug with one-log cell killing at 1 Ã¬M of gemcitabine. The polymersome was also able to
control the release of gemcitabine, and this release was modulated by the degradation kinetics of the
ester linkages in the membrane. Photodynamic therapy was performed against OVCAR-5 (ovarian cancer)
cells. A hydrophobic photosensitizer, benzoporphrin derivative monoacid A (BPD-MA) was encapsulated
the in the membrane of polymersomes composed of PEO14-PBD22 (OB14.5) polymer, and its
phototoxicity was compared to an existing photosensitizer formulation called verteporfin that is currently
used in the clinic for age-related macular degeneration (AMD). The polymersome formulation
outperformed verteporfin both at the in vitro and in vivo level. Additionally, we investigated the
photorupture of giant polymersomes encapsulating a near IR fluorophore (porphyrin dimer, PZn2) in the
hydrophobic membrane and dextran in the aqueous lumen. Polymersomes synthesized from softer
polymers released more of a reporter dye than stiffer polymersomes when illuminated with 690 nm of
light. Finally, we investigated the fractionation of giant polymersomes in a deterministic lateral
displacement device and developed a hydrodynamic model to predict this fractionation based on the
attractive and repulsive forces experienced by the polymersome.
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ABSTRACT

MULTI-FUNCTIONAL POLYMER VESICLES: APPLICATIONS IN DRUG DELIVERY
AND PHOTODYNAMIC THERAPY
Nimil Sood
Daniel A. Hammer, Ph.D.
The field of drug delivery is rapidly expanding to bridge the gap between novel drugs
that are created and their effective entry into diseased tissue. In one growing area of
research, synthetic polymers are being utilized to meet these needs. The precise control
over their chemistry allows polymers to be tuned to the drug delivery application and
make them attractive candidates for research. The focus of this dissertation is to
engineer responsive polymersomes for drug delivery and understand their ability to
reduce drug toxicity, increase absorption in diseased cells and tissue, and control the
release of drug in vitro and in vivo. Gemcitabine, a nucleoside analog, was encapsulated
in the aqueous core of nano-polymersomes composed of the biodegradable and
biocompatible polymer PEO-PCL, and the in vitro toxicity of this novel drug delivery
construct was tested against Panc-1 cells. The polymersome formulation performed at
par with the free drug with one-log cell killing at 1 µM of gemcitabine. The polymersome
was also able to control the release of gemcitabine, and this release was modulated by
the degradation kinetics of the ester linkages in the membrane. Photodynamic therapy
was performed against OVCAR-5 (ovarian cancer) cells. A hydrophobic photosensitizer,
benzoporphrin derivative monoacid A (BPD-MA) was encapsulated the in the membrane
of polymersomes composed of PEO14-PBD22 (OB14.5) polymer, and its phototoxicity
was compared to an existing photosensitizer formulation called verteporfin that is
v

currently used in the clinic for age-related macular degeneration (AMD). The
polymersome formulation outperformed verteporfin both at the in vitro and in vivo level.
Additionally, we investigated the photorupture of giant polymersomes encapsulating a
near IR fluorophore (porphyrin dimer, PZn2) in the hydrophobic membrane and dextran
in the aqueous lumen. Polymersomes synthesized from softer polymers released more
of a reporter dye than stiffer polymersomes when illuminated with 690 nm of light.
Finally, we investigated the fractionation of giant polymersomes in a deterministic lateral
displacement device and developed a hydrodynamic model to predict this fractionation
based on the attractive and repulsive forces experienced by the polymersome.
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1 Introduction to Synthetic Polymers as
Drug Delivery Vehicles and the
Specific Aims of this Dissertation
1.1 Challenges in Drug Delivery
With significant advancement in the field of medical science, new classes of
pharmaceuticals and biologics are paving the way for the rapid evolution of drug delivery
technologies. The underlying challenges in drug delivery, however, have remained fairly
constant. Drug solubility and stability in the body, method of administration (oral,
intravenous, transdermal, intramuscular, etc.), and drug absorption, distribution,
metabolism, and elimination all are critical parameters that determine the overall efficacy
and toxicity of a drug. The design of new drugs takes into account these considerations.
Because of the complexity of new treatments, engineering smart delivery vehicles is
often done in tandem with drug development. Figure 1-1 illustrates the fate of a drug and
drug delivery vehicle from its introduction into the body to its ultimate metabolization and
elimination. Stable drug carriers must navigate the harsh in vivo environment to
successfully deliver the therapeutic payload to the appropriate site.
1

Figure 1-1: Diagram illustrating how drugs are absorbed, distributed, metabolized, and excreted from the
body. Adapted from [1].

The work presented in this thesis focuses on the utility of synthetic polymers for
the delivery of therapeutic drugs to cancer cells. The next section outlines the use of
polymersomes, self-assembled polymer vesicles, for drug delivery applications.

2

1.2 Introduction to Polymersomes as Drug Delivery Vehicles
Polymersomes are self-assembled vesicles composed of amphiphilic block
copolymers. In aqueous solution, these polymers undergo spontaneous reordering that
yield mesoscopic structures ranging in size from hundreds of nanometers to tens of
microns [2]. Much like the packing parameter [3] ( 𝑣/𝑎0 𝑙𝑐 ) established for the selfassembly of lipids in solution – where the ratio of the hydrophobic tail volume 𝑣 to the
product of the head group area 𝑎0 and hydrophobic tail length 𝑙𝑐 give different structures
in solution ranging from micellar to bilayer vesicles – a general rule of thumb exists for
polymersomes as well. The hydrophilic to total mass fraction guides the assembly of
various structures. This is highlighted in Table 1-1.

Table 1-1: General guidelines for the self-assembly of block copolymers in solution. Adapted from [2].

𝑓ℎ𝑦𝑑𝑟𝑜𝑝ℎ𝑖𝑙𝑖𝑐

Shape Factor

𝑓 < 25%

Inverted microstructure

25% < 𝑓 < 35%

Bilayer vesicle

𝑓 > 45%

Micelle

Polymersomes have significant advantages over liposomes. While both vesicles have an
aqueous core and hydrophobic membrane, the hyperthick polymer membrane can
encapsulate a much larger payload of hydrophobic molecules. Lipid membranes have a
thickness of around 3 nm whereas polymersomes can have varying membrane
thicknesses ranging from

8 nm to 21 nm [4]. Polymersome membranes are also

mechanically more robust than liposome membranes. Typical values of membrane
elastic moduli, as determined from micropipette aspiration, are around 100 dyne/cm for
polymersomes and 150 to 1000 dyne/cm for liposomes [4, 5]. The surface chemistry of
polymersomes can be readily altered to include targeting moieties. Previous work has
been done to conjugate a TAT peptide on the surface of polymersomes to enhance the
3

uptake of vesicles by dendritic cells [6]. The improved mechanical robustness,
hydrophobic

encapsulation

potential,

and

surface modification

potential

make

polymersomes ideal candidates for targeted drug delivery applications.

1.3 Specific Aims
Aim 1: Develop controlled release nano-polymersome platform for the encapsulation
and release of chemotherapeutic drug and determine toxicity in cancer cells.
Aim 2: Quantify the release

of

an encapsulated fluorescent

dye from giant

polymersomes due to photo-initiated rupture.
Aim 3: Encapsulate a photosensitizer in nano-polymersomes for photodynamic therapy
and assess the in vitro and in vivo toxicity of the polymersomes.
Aim 4: Develop a force-based model for understanding and predicting polymersome
fractionation in a deterministic lateral displacement microfluidic device.

1.4 Description of Dissertation
This dissertation is composed of six chapters and describes the efforts to create
controlled release polymersomes for the delivery of therapeutic molecules to in vitro or in
vivo cancer models.

Chapter 2 presents the preparation and characterization of nano-polymersomes
synthesized from PEO-PCL that encapsulate a chemotherapeutic drug called
gemcitabine. Like many other chemotherapeutic drugs, gemcitabine has a short half-life
in the blood and severe dose limiting toxicities. Encapsulating gemcitabine within
4

polymersomes can mitigate these side effects, increase the blood circulation time, and
produce greater toxicity at the cancer site. We can passively control the release of
gemcitabine from the polymersomes by taking advantage of the PCL block degradation
under acidic conditions.

Chapter 3 presents an extension of controlled release polymersomes. In this
chapter, we illustrate and quantify the photoresponsiveness of giant polymersomes that
contain a hydrophobic solute in the membrane (porphyrin) and a hydrophilic solute in the
aqueous lumen (dextran). Under certain illumination conditions, these polymersomes
undergo membrane deformation and rupture. This work has implications in the field of
drug delivery since we can actively control the release of encapsulated molecules.

Chapter 4 presents the work done to synthesize and characterize nanopolymersomes that encapsulate a photosensitizer for photodynamic therapy (PDT). PDT
provides an interesting approach to cancer therapy because the cytotoxic agent is not a
small molecule drug but actually singlet oxygen. Singlet oxygen is generated locally by
first administering a photosensitizer, and then illuminating the diseased tissue with a
specific wavelength of light. A polymersomal formulation of the photosensitizer provides
several advantages over current formulations, with the additional benefit of having a dual
drug delivery vehicle encapsulating both a photosensitizer in the hydrophobic membrane
and chemotherapeutic drug in the aqueous lumen.

Chapter 5 is a departure from the topic of nanoparticle drug delivery. In this
chapter, I discuss the experimental and computational modeling work done to
understand the fractionation of giant polymersomes in a deterministic lateral
displacement microfluidic device. Synthesizing monodisperse polymersomes form thin5

film rehydration is extremely challenging. Other methods of synthesizing polymersomes
(emulsion techniques, electroporation) result in a monodisperse population but low yield.
Combining the rehydration technique with a fractionation will give a large number of
polymersomes of a desired size.

Finally, Chapter 6 details the major findings and future directions of the work
presented in this dissertation.

6
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2 Biodegradable Polymersomes for the
Delivery of Gemcitabine to Panc-1
Cells
2.1 Summary
Traditional anti-cancer chemotherapy often displays toxic side effects, poor
bioavailability, and a low therapeutic index. Targeting and controlled release of a
chemotherapeutic agent can increase drug bioavailability, mitigate undesirable side
effects, and increase the therapeutic index. Here we report a polymersome-based
system to deliver gemcitabine to Panc-1 cells in vitro. The polymersomes were selfassembled

from

a

biocompatible

and

completely

biodegradable

polymer,

poly(ethyleneoxide)-poly(caprolactone), PEO-PCL. We showed that we can encapsulate
gemcitabine within stable 200 nm vesicles with a 10% loading efficiency. These vesicles
displayed a controlled release of gemcitabine with 60% release after 2 days at
physiological pH. Upon treatment of Panc-1 cells in vitro, vesicles were internalized as
verified with fluorescently labeled polymersomes. Clonogenic assays to determine cell
survival were performed by treating Panc-1 cells with varying concentrations of
8

unencapsulated gemcitabine (FreeGem) and polymersome-encapsulated gemcitabine
(PolyGem) for 48 hours. 1 μM PolyGem was equivalent in tumor cell toxicity to 1 μM
FreeGem, with a one log cell kill observed. These studies suggest that further
investigation on polymersome-based drug formulations are warranted for chemotherapy
of pancreatic cancer.

2.2 Introduction
Pancreatic adenocarcinoma is the fourth highest cause of cancer death with a 5year survival rate of less than 6% [1]. Despite the use of surgery, radiation and/or
chemotherapy [2], local recurrence and metastasis invariably occur.

The causes of

resistance of pancreatic tumors are not completely understood. The inability to deliver
adequate adjuvant therapy due to local normal tissue toxicity, limitations caused by
tumor microenvironment (hypoxia, pH), and active drug export out of tumor cells likely
cause this resistance [3-4].

Modifications to the delivery of chemotherapeutics that

improve the therapeutic ratio (TR) are highly desirable in order to allow higher drug
delivery while minimizing toxicity to normal tissues.

Gemcitabine is a commonly-used water soluble anticancer agent that acts as an
anti-metabolite; it is considered an efficacious addition to radiation therapy in pancreatic
cancer

[5].

Gemcitabine

is

an

S-phase

deoxycytidine

analog

(2’,2’-

difluorodeoxycytidine). Its mechanism of action involves competitive incorporation into
DNA, masked termination (causing termination of DNA synthesis without being excised
out of the strand), and self-potentiation (promoting its own activity by inhibiting regulatory
enzymes involved in DNA synthesis). Like most chemotherapeutics, its use has
significant limitations. Gemcitabine is rapidly metabolized in the blood stream with a

9

short plasma half-life (for short infusions, 32 - 94 min) and has substantial side effects
that limit the dose that can be given, especially when combined with radiation therapy
[6]. In a phase 1 study, concurrent application of gemcitabine and radiation caused
nausea, vomiting, dehydration and gastric ulceration resulting in a 44% hospital
admission rate [7]. These side effects are much greater for concurrent therapy than for
just radiation, which has been linked primarily to nausea. Encapsulation of gemcitabine
in a carrier vehicle has the potential to reduce dose-limiting side effects while improving
the drug delivery to the tumor.

The latter includes increased circulation time and

preferential accumulation in tumor due to the enhanced permeability and retention (EPR)
effect [8].

Encapsulation of gemcitabine to address the challenges of rapid blood
metabolism and low therapeutic ratio has been previously investigated. In one study,
gemcitabine loaded in sonochemically-prepared bovine serum albumen (BSA)
microspheres, was evaluated for cell killing in renal cancer in vitro [9]. These
microspheres exhibited poor dynamics of release and were unable to take advantage of
the EPR effect observed in solid tumors due to their large size (~1 μm diameter), an
effect which requires 150-300 nm particles in diameter [8]. In another study, albumin
nanospheres were loaded with gemcitabine [10]; this delivery system also had poor
release kinetics with 100% of the drug being released in 24 hours. In a third study,
encapsulated gemcitabine within poly(ethylene glycol)-poly(DL-lactic acid) (PEG-PDLLA)
nano-vesicles showed toxicity against SW1990 pancreatic cells [11]. The vesicle
morphology and size of these vesicles were very variable.

Polymer vesicles, or polymersomes, are self-assemblies of amphiphilic block
copolymers that can encapsulate both hydrophobic and hydrophilic compounds [12-13].
10

Their highly tunable chemistry allows for diverse functionalities and applications [14].
Polymersomes possess superior biomaterial properties compared to their lipid
counterparts

(liposomes)

including

greater

stability,

storage

capacity,

release

characteristics, and plasma circulation times [15-18]. The hydrophilic block is often
composed of poly(ethylene oxide) (PEO) head groups, which helps reduce non-specific
interactions with blood proteins due to their hydrophilicity and steric hindrance effects.
This greatly reduces opsonization of nanoparticles and increases their plasma circulation
time. Several biodegradable hydrophobic blocks can be utilized for drug delivery
including polycaprolactone (PCL) and polylactide (PLA) for polymersomes and
polylactic-co-glycolic acid (PLGA) for nanoparticles [14, 19-21]. PCL has several
advantages over the other polymers including high permeability to small molecules,
maintenance of neutral pH after degradation, ease of blending with other polymer
blocks, and long-term and tunable erosion kinetics [22].

Recognizing the potential of PEO-PCL polymersomes for use in cancer
treatment, this manuscript describes the novel use of PEO-PCL nano-polymersomes for
gemcitabine encapsulation and in vitro delivery to Panc-1 cells. We investigated the
polymersome release kinetics of gemcitabine, vesicle internalization by Panc-1 cells,
and cell toxicity of PolyGems compared to standard gemcitabine (FreeGem).
Polymersomes were internalized by Panc-1 cells and had equivalent cell toxicity at the
same total dose when loaded with gemcitabine. These results suggest that PolyGems
have the potential to be an attractive route to improve gemcitabine delivery in vivo.

11

2.3 Materials and Methods
2.3.1 Materials
Gemcitabine (Gemzar ®) was obtained from Eli Lilly and Company (Indianapolis,
IN). Panc-1 cells were obtained from the ATCC. DMEM/F12 Ham’s (50/50) without
phenol red was purchased from ZenBio (Research Park, NC). The meso-to-meso ethyne
bridged (porphinato) zinc(II) trimer (PZn3) with a 9-methoxy-1,4,7-trioxanonyl substituent
on one aryl group and a more hydrophobic 3,3-dimethyl-1-butyloxy substituent on the
other, was synthesized as previously described [23]. Glacial acetic acid, methylene
chloride, methylene blue for colony staining, phosphate buffered saline (PBS), sodium
acetate trihydrate, and sodium chloride were purchased from Fisher Chemicals
(Pittsburgh, PA). Polycarbonate extrusion membranes (13 mm) were purchased from
Whatman (Piscataway, NJ). Centrifugal filter units were purchased from Millipore
(Billerica, MA). Dialysis cassettes were purchased from Spectrum Laboratories (Rancho
Dominguez, CA).

2.3.2 PEO-PCL Preparation
PEO-b-PCL with 45 and 105 monomer repeat units per block, respectively (MW
= 14,000 g mol-1) was synthesized prior to this work [14]. The block co-polymer was
generated

via

ring-opening

polymerization

of

cyclic

ε-caprolactone.

Briefly,

monomethoxypoly(ethylene oxide) (2k) was filled in a flame-dried flask under argon.
Caprolactone monomer was injected into the flask via syringe and two drops of
stannous(II) octoate was added to the reaction mixture. The reaction occurred at 130°C
for 24 hours. The copolymer was isolated by dissolving the product in methylene
chloride and precipitating in excess methanol/hexane at 4°C. The resulting powder was
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dried further. The block co-polymer was purified via gel permeation chromatography and
the molecular weight was determined by 1H NMR.

2.3.3 Vesicle Preparation
Polymersomes were synthesized by the thin film hydration method as described
elsewhere [14]. Briefly, 200 μL of a 100 mg/mL PEO-PCL solution in methylene chloride
were deposited on a roughened Teflon strip and allowed to dry overnight under vacuum.
A 2.21 mg/mL (corresponding to 5:1 molar ratio of drug:polymer) solution of gemcitabine
in 0.9% saline (~290 mOsm) was added to the film in a 20 mL vial in order to hydrate the
polymer. Polymersomes were formed by one hour of sonication at 60°C and 5
freeze/thaw cycles using liquid nitrogen. A narrow size distribution of polymersomes was
obtained by successive extrusion through 400 nm, 200 nm, and 100 nm membranes
using a thermobarrel extruder (Lipex Biomembranes, Vancouver, Canada) operating at
65°C. Size was verified using a NanoZs Zetasizer (Malvern Instruments, Southboro,
MA). 0.9% saline without drug was used as the hydration solution for control studies. For
cellular uptake studies, polymersomes were loaded with the porphyrin-based near-IR
fluorophore, PZn3 (λex = 785 nm, λem = 800 nm), at a molar ratio of 40:1 polymer to PZn3
by cocasting the PZn3 with the polymer film. Before cell culture studies, vesicles were
sterilized for 30 minutes via germicidal UV irradiation.

2.3.4 Cryo-TEM
Cryogenic Transmission Electron Microscopy was performed at the University of
Pennsylvania in the Penn Regional Nanotechnology Facility (Philadelphia, PA). Lacey
formvar/carbon grids (Ted Pella) were rinsed with chloroform to remove the formvar
template and subsequently carbon coated with a Quorum Q150T ES carbon coater
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(Quorum Technologies, United Kingdom). Grids were cleaned with hydrogen/oxygen
plasma for 15 seconds using the Solarus Advanced Plasma System 950 (Gatan,
Pleasanton, CA). Polymersome sample (2µL) was deposited on lacey formvar/carbon
mesh grid (Ted Pella) and inserted into a cryoplunger (Gatan Cp3, Gatan). The sample
was blotted by hand and plunged into liquid ethane. Samples were transferred to a
cryoholder (Gatan CT3500TR, Gatan) and the cryoholder was immediately inserted into
a JEOL 2010 TEM (JEOL) operating at 200 kV. Micrographs were imaged with an Orius
SC200 digital camera.

2.3.5 Vesicle Release Kinetics
Nano-vesicles were prepared as described above. After extrusion, vesicles were
concentrated to 0.5 mL volume using 3 kDa centrifugal filters made from regenerated
cellulose. Additional removal of unencapsulated drug was performed via dialysis against
a pH 5.0 sodium acetate/sodium chloride buffer (acidified with glacial acetic acid) or pH
7.4 PBS buffer. Immediately following dialysis, 250 μL sample aliquots were placed in
microdialysis tubes and stored in 22 mL of pH 5.0 or 7.4 buffer in a 37°C oven. At
predefined time points, aliquots were taken from the buffer solution and read on a
UV/Vis spectrophotometer at 270 nm (ε = 9.86 x 10-3 cm-1 μM-1). Aliquots were returned
to the buffer to maintain a constant volume. 100% release was determined by addition of
100 μL of a 1% Triton-X solution to the PolyGem vials after one week and the
gemcitabine absorbance after overnight storage at 37°C was measured.

2.3.6 Cell Culture
At the time of receipt from the ATCC, cells were placed in cryo-vials and stored in
liquid nitrogen for future use. Cells for study were defrosted using standard procedures.
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New cell stock was defrosted at 6-month intervals. Panc-1 cells were cultured in
DMEM/F12 Ham’s (50/50) without phenol red and with 12% fetal calf serum and 1%
Pen/Strep. Cells were maintained in T-75 plastic culture flasks at 37°C in a humidified
atmosphere containing 5% CO2 in air. Flasks were subcultured when they were 75 –
90% confluent. Five minute exposure to 0.05% trypsin-EDTA was used to release
attached cells from the tissue culture surface.

2.3.7 In Vitro Cellular Uptake of Vesicles
Fluorescent polymersomes were synthesized as described above. The
concentration of PZn3 was determined by Beer’s Law using the established extinction
coefficient ε(795nm) = 1.25 cm-1 μM-1 [24]. Panc-1 cells were plated in triplicate at 5,000
cells per well in 96 well (black frame, clear well) cell culture plates (Isoplate-96 TC,
Perkin Elmer). Cells were allowed to adhere overnight. The following day, varying
concentrations of fluorescent polymersomes were added to wells and were incubated for
12, 24, and 48 hours. At each time point, one plate was removed from incubation,
washed three times with media to remove all polymersomes that were not internalized.
Vesicles were illuminated on a LICOR Odyssey (λex = 488 nm, λem = 810 nm). A
calibration curve was generated to relate the fluorescence signal from wells to the
concentration of PZn3 to determine cellular uptake. Confocal laser scanning microscopy
(CLSM) was used to visualize vesicle internalization in Panc-1 cells incubated with
fluorescent polymersomes for 12 hours. An Olympus Fluoview FV1000 confocal
microscope (Center Valley, PA) with a PLFLN 40x oil objective lens was used to obtain
z-stacks of cells with a scan speed of 8.0 μs pixel-1 and step size of 1μm.
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2.3.8 In Vitro Toxicity
Panc-1 cells were plated onto 60 mm tissue culture dishes. After 48 hours, the
plates were examined under the microscope for evidence of cell growth. Only plates
containing of 50-90% confluent cells were used for study. Following the removal of spent
media, the plates were rinsed with 2 mL of fresh media. The rinse media was then
replaced with 2 mL of treatment solution (Polygem, FreeGem, or blank polymersomes).
Dishes were incubated for an additional 48 hours. At the time of assay, cells were
removed from the plate by incubating 2 mL of 0.05% trypsin-EDTA with the cells for 5
minutes at 37°C. Trypsin was inactivated using fresh media with serum, and the total cell
number was determined using a Coulter counter. A clonogenic assay was performed
using standard techniques [25]. Plates were incubated for two weeks, with the goal of
obtaining 25-250 colonies per plate. The surviving fraction was determined by
normalizing the colony count of the treated condition by the initial cell number plated.
The concentration of gemcitabine as reported for PolyGem represents the total
encapsulated concentration. We corrected for the drug release relative to time, which
was 60% release at 48 hours. The survival graphs were presented in absolute fractions
with the maximal plating efficiency of untreated Panc-1 cells being 0.60. All comparisons
were made to this value. Qualitative morphology of treated cells was observed using a
Zeiss inverted microscope. Panc-1 cells were treated with media, 5 μM FreeGem, 5 μM
PolyGem, or 2.5 μM blank polymersomes.

2.3.9 Statistical Analysis
All experiments were performed in triplicate, except where noted. In vitro toxicity
studies were performed in duplicate with varying amounts of initial cell plating to ensure
the resulting colonies were within a countable range (50-200 colonies). Data were
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reported as mean ± standard deviation and analyzed by Single Factor ANOVA, setting
the level of significance at p < 0.05.

2.4 Results and Discussion
Despite the advancement of chemoradiation therapy for the treatment of
pancreatic cancer, the 5-year survival rate continues to among be the lowest of solid
tumors. Any improvement in the delivery of chemotherapeutics to pancreatic cancer
should mitigate side-effects associated with treatment and improve the survival outlook
for patients. In the studies reported herein, we created a prototype vehicle which could
ultimately be capable of delivering gemcitabine, a potent pancreatic cancer drug, to
pancreatic cancer. The major aim of this work was to perform a comparative in vitro
study of the cell-killing efficacy of polymersome-encapsulated gemcitabine (PolyGem)
and unencapsulated gemcitabine (FreeGem) on Panc-1 cells.

2.4.1 Vesicle Preparation and Characterization
Bioresorbable polymersomes were synthesized via the thin-film rehydration
method

from

two

FDA-approved

polymers,

poly(ethylene

oxide)

(PEO)

and

poly(caprolactone) (PCL), which were covalently linked to form a diblock copolymer.
PEO-PCL self-assembled in a fashion such that the hydrophobic PCL block was
embedded in the polymersome membrane and the PEO block was exposed on the outer
vesicle surface and inner corona. Thin-film rehydration is particularly attractive for
making polymersomes for biological applications as it does not require the use of
potentially toxic organic solvents during the hydration step (as is employed in the solvent
injection method) [26]. Figure 2-1 shows a schematic of our novel carrier.
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Figure 2-1: Schematic representation of PolyGem. In aqueous solution, poly(ethylene oxide)-bpoly(caprolactone) (PEO-PCL) self-assemble into spherical polymer vesicles (polymersomes), with the
hydrophobic PCL chains orienting end-to-end to form the bilayer. The figure represents a uniaxial cross
section of the polymersome, with gemcitabine ( ) encapsulated in the aqueous lumen. Vesicles can also be
made to include PZn3 ( ) in the hydrophobic membrane.

The size distribution of vesicles was measured using dynamic light scattering
(DLS) and is shown in Table 2-1. Vesicles were serially extruded through 400, 200, 100,
100, and 200 nm polycarbonate membranes to reduce the sample polydispersity. The
average hydrodynamic diameter of PolyGems was 180 nm. The hydrodynamic diameter
of blank polymersomes (181 nm) and PZn3-polymersomes (180 nm) did not statistically
vary from PolyGems (p > 0.05).
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Table 2-1: Hydrodynamic diameter and polydispersity of different polymersome formulations.

Vesicles were stored at 4ºC and used in the studies within one week of
preparation. We evaluated the stability of gemcitabine after sonication and freeze/thaw
cycles by checking the absorbance of the drug before and after processing. There was
no difference in the absorbance spectrum, indicating that the drug retained its structure.

2.4.2 Vesicle Drug Release
To improve the tumor-killing effect of drug delivery vesicles in vivo, maximal drug
release should occur between 10 and 20 hours following injection, during which time the
majority of vesicles have accumulated at the tumor and can cause toxicity [27]. In order
to approximate the time constants of release of gemcitabine in vivo, we first explored the
in situ release of gemcitabine from PolyGems under acidic (pH 5.0) and physiological
conditions (pH 7.4) as shown in Figure 2-2. Approximately 20% of the gemcitabine is
released from the PolyGems within the first few hours at both pHs. The concentration of
gemcitabine released begins to level off at approximately day two, indicating stable and
controlled release after an initial period up to 48 hours.
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Figure 2-2: Cumulative in situ release of gemcitabine from PolyGem. Release was measured at pH 5.0
and 7.4 at 37ºC. Gemcitabine was detected via UV/Vis spectroscopy for 7 days. N = 3 for each data point
and the error bars represent standard deviation.

The release curves are well fit by a function of the form c/c 0 = α(1 – e

– t/τ

), where

α is a lumped constant and τ is the characteristic time constant. This functional form can
be derived from a 1-D analysis of drug diffusion across a semi-permeable membrane.
Fitting this equation to the release curves in Figure 2-2 reveal that τpH5 is 12 hours and
τpH7 is 16 hours (lower values of τ indicate more rapid release). These time constants
describe the time required for 63% (1 – 1/e) of the drug to be released due to diffusion,
and are functions of polymersome properties including geometric radius, membrane
thickness, and diffusivity and partition coefficient of gemcitabine in the membrane. The
time constants verify the quicker release observed at acidic conditions, with τpH5 equal to
12 hours and τpH7 equal to 16 hours. The ideal time constant for release depends on the
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time required for polymersomes to localize at a tumor site. Minimal drug should be
released due to passive diffusion while the vesicles are still en route, and maximal and
prolonged release should occur when vesicles have reached the tumor. As seen from
the release curves, the majority of the gemcitabine was released within 2 days, which is
consistent with the 10-20 hour window observed by Ahmed and coworkers [27].

A burst release of drug was observed during the first few hours, which was likely
caused by the initially steep concentration gradient of gemcitabine present across the
vesicle membrane, leading to a high initial diffusive flux. One explanation of this
observation is that some entrapped gemcitabine in the outer PEO corona may have also
contributed to the burst. Gemcitabine release was greater at all time points under acidic
pH as compared to physiological pH. The PCL block is known to undergo hydrolysis of
its ester linkages in solution, with a higher rate of degradation observed at acidic pHs as
compared to physiological pHs [28-29]. Consequently, both membrane permeability and
the diffusive flux of gemcitabine increased at pH 5.0.

2.4.3 Cryo-TEM of Vesicles
In order to understand the difference in observed release rate between vesicles
at pH 5.0 and 7.4, we observed the structure of nanovesicles using cryo-TEM at the
incubation different conditions. Figure 2-3 provides representative images of vesicles
that have been incubated at either pH 7.4 (Figure 2-3A) or pH 5.0 (Figure 2-3B-D) for 12
hours. The vesicles in Figure 2-3A have an even membrane thickness that is indicative
of an intact membrane. The vesicles in Figure 2-3B-D have compromised membranes
as shown by the arrows. In Figure 2-3B, the membrane of one vesicle has completely
disintegrated and has formed a pore. Figure 2-3C shows a vesicle with a thinning portion
of the membrane. Finally, in Figure 2-3D we see a membrane pore starting to form.
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Figure 2-3: Cryo-TEM micrographs of PEO-PCL vesicles. Images were taken 12 hours after incubation at
37C at (A) pH.7.4 and (B)-(D) pH 5.0.Arrows indicate areas of membrane degradation. Scale bar = 100 nm.

Understanding the release at pH 5.0 is especially important for in vivo delivery to
tumors because the extracellular environment of many tumors is acidic [30-32].
PolyGems would likely experience both acidic and physiological pH as they reach the
tumor.

2.4.4 In Vitro Cellular Uptake
While it is known that polymersomes will partition into tumor tissue in vivo [24],
cellular internalization of the vesicles at the tumor is desirable so the chemotherapeutic
cargo can be released inside the cell in addition to the interstitial spaces where plasma
clearance could be problematic. We visualized polymersome internalization by a cellular
uptake study of blank polymersomes loaded with a hydrophobic porphyrin-based NIR
fluorophore, PZn3, in the vesicle membrane. PZn3-based polymersomes have been
utilized in the past to investigate polymersome uptake in dendritic cells (DCs) and DC
trafficking in vivo [33-34]. In our study, Panc-1 cells were incubated with 50, 250, or 500
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nM of PZn3-loaded polymersomes in 96 well plates for 12, 24, or 48 hours. A calibration
was performed to relate the integrated intensity in wells to PZn3 concentration. Figure
2-4 shows the concentration of internalized PZn3 as a function of incubation time.
Vesicle uptake increased with an increase in the concentration of PZn3 as well as
incubation time. In order to confirm that the internalization from the uptake study was not
surface association, Panc-1 cells were incubated with 500 nM PZn3 for 12 hours and
imaged on a confocal microscope with 1 μm z-slices. Figure 2-4C shows z-slices starting
from the top of the cell and moving to the bottom. Vesicles are only observed internally
and not on the cell surface.

Figure 2-4: PolyGem internalization by Panc-1 cells. (A) Fluorescence intensity of PZn3-polymersomes
internalized by cells in well plates corresponding to 48 hour time point. (B) Concentration of PZn 3 uptake as
a function of solution PZn3 concentration (n = 3). Error bars indicate standard deviation. (C) CLSM z-stack
images of Panc-1 cells incubated with PZn3-polymersomes for 12 hours. Z-slices (Δz = 3 μm) are presented
from left to right. Scale bar = 50 μm.

The uptake study of PolyGems showed that vesicle internalization is a
concentration- and time-dependant process with more internalization occurring for higher
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polymersome number and longer incubation times. However, a relatively low percentage
of vesicle internalization was observed.

A likely contributor is the stealth character

imparted by the PEO block to the PolyGem, rendering the vesicles virtually invisible to
Panc-1 cells. Another possible reason for low uptake could be a reduced cell surface
area available for internalization due to cell adhesion on a tissue culture plate. Christian
and coworkers observed a similar trend when incubating PZn3-polymersomes with
dendritic cells. Negligible uptake was noticed for vesicles decorated with a PEO brush as
compared to vesicles surface-conjugated with the HIV-derived TAT peptide [33].

2.4.5 In Vitro Cell Toxicity
Panc-1 cell survival was determined by a clonogenic assay following 48 hour
FreeGem or PolyGem exposure using varying drug concentrations (Figure 2-5). Panc-1
survival is concentration dependent with an observed increase in cell kill as gemcitabine
concentration was increased irrespective of the formulation used. A one log cell kill is
observed at approximately 1 μM gemcitabine, irrespective of the formulation. The only
drug concentration where there was a significant difference in survival between
FreeGem and PolyGems was at 0.05 μM gemcitabine (p = 0.048) where the PolyGem
were more effective than the FreeGem. There was no significant cell kill using either
blank polymersomes (0 μM PolyGem) or media-only treatment (0 μM FreeGem) as seen
in Figure 2-5.
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Figure 2-5: Panc-1 survival curve. Viability was determined after 48 hour treatment with varying
concentrations of FreeGem or PolyGem, as measured by a clonogenic assay. Error bars indicate standard
deviation (n = 3). * p < 0.05.

To qualitatively assess cell toxicity, Panc-1 cells were imaged using differential
interference contrast microscopy (DIC) following 48 hour exposure to media, 5 μM
FreeGem, 5 μM PolyGem, or 2.5 μM blank polymersomes. These doses of PolyGem,
FreeGem, and blank polymersomes were chosen to reflect the maximum concentration
of gemcitabine delivered to Panc-1 cells in the clonogenic assay and to equate the
concentration of PEO-PCL across the formulations (2:1 ratio of drug to polymer). Figure
2-6A and Figure 2-6B demonstrate that application either of media or blank
polymersomes, respectively, have no effect on cell viability since the cells are
morphologically normal. Both 5 μM FreeGem and 5µM PolyGem treatments (Figure
2-6C and Figure 2-6D, respectively), resulted in significant cell killing as observed by the
presence of morphologically abnormal cells and cellular debris.
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Figure 2-6: Cell phenotype as visualized by DIC. (A) Media control, (B) 2.5 μM empty polymersomes, (C)
5 μM FreeGem, and (D) 5 μM PolyGem. Scale bar = 100 μm.

Despite the low uptake without any targeting peptides, PolyGems performed at
par with FreeGem (Figure 2-5). We believe that PolyGems released gemcitabine into the
cell media, which was then internalized along with some vesicles via endocytosis and
eventually leading to toxicity.

2.5 Conclusion
The true potential of PolyGems can best be determined in vivo where the drug
kinetics are affected by all aspects of the tumor microenvironment, and the therapeutic
ratio (TR) can be assessed. This ratio is optimally greater than one under in vivo
conditions. Gemcitabine-based chemoradiotherapy in pancreatic cancer currently has a
very narrow TR, being very close to one [35-36]. The result is substantial toxicity to the
GI tract. We propose that this TR can be improved in future studies using the PolyGem
technology. These nano-vesicles encapsulate and release gemcitabine over a prolonged
period of time, which will likely be sufficient for non-specific accumulation of PolyGems
26

at the tumor site due to the EPR effect. A higher local concentration of drug in the tumor
interstitial fluid can be expected because the polymersome prevents significant
degradation of gemcitabine while trafficking to the tumor site. We predict that
endocytosis of both free drug (due to release from the vesicles) and a portion of
encapsulated drug will occur. The current findings – no decreased toxicity of
gemcitabine using the encapsulated agent at equal concentrations of the free agent –
are encouraging and support performing in vivo studies. Future studies will also focus on
increasing efficacy by engineered internalization (i.e., using TAT-peptides conjugated to
the polymersome surface) and targeting to specific cell surface receptors.
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3 Light Responsive Polymersomes:
Understanding the Light Dose
Response of Soft Vesicles
3.1 Summary
Altering membrane properties of soft vesicles can be of great interest in the field of
generating synthetic cells that can mimic biological function. It has been recently shown
that polymersomes encapsulating a near IR porphyrin fluorophore in the hydrophobic
membrane and dextran in the aqueous lumen undergo membrane instability when exited
with visible light. With drug delivery as a motivating factor, causing this membrane
stability to occur at low laser power and induced by near IR light can be quite beneficial.
The work presented here describes a soft vesicle system that undergoes photorupture
from 690 nm light at low light doses. Furthermore, we quantify the rupture of these
vesicles by determining the release percentage of an encapsulated fluorescent
molecule, sulforhodamine B. We compared the release from vesicles composed of soft
and stiffer membranes and quantify up to 40% release from the soft vesicles after 100
J/cm2 of 690 nm light delivery.
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3.2 Introduction
Polymersomes are bilayer vesicles self-assembled from amphiphilic copolymers
[1]. Because of their robust chemical and mechanical properties, polymersomes have
played an important role in therapeutic and diagnostic (theranostic) applications in drug
delivery for cancer [2, 3], developing biomimetic systems to understand cellular
processes [4], and acting as in situ mechanical stress sensors [5]. Polymersomes in the
field of drug delivery have received particular attention. The large aqueous core and
hyperthick

hydrophobic

membrane

are

capable

of

encapsulating

significant

concentrations of both hydrophilic and hydrophobic drugs, respectively, effectively
providing a protective shell that increases drug circulation time in vivo [6]. There are
several engineering challenges associated with synthesizing these polymersomes, and
one of them is the release mechanism of the drug from the delivery vehicle.

Several polymersome systems rely on internal release mechanisms such as pH,
temperature, and redox potential to release the encapsulated cargo. The method of
vesicle destabilization include altering the hydrophilicity of the polymer [7] or degrading a
polymer block [6, 8, 9]. These internal release mechanisms take advantage of the tumor
microenvironment, which is known to be acidic and reducing [10-12]. These harsh
microenvironments cause polymersomes to undergo shape changes (vesicular to
micellar) or increase the permeability of the membrane to facilitate drug diffusion across
the hydrophobic membrane. While internal release mechanisms provide an escape route
for drugs from the carrier, they are ultimately dependent on the highly variable
microenvironment. The transition from internal release mechanisms to external
mechanisms is advantageous because it could provide precise spatiotemporal control
over drug delivery.
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Recently, groups have reported light-mediated release from polymersomes. Light
is an attractive external release trigger because it is noninvasive and can be directed at
the desired site of release (eg. tumor). Typically, these systems contain light-activated
linkers that combine the hydrophilic and hydrophobic blocks of the diblock copolymer.
Upon excitation with light ranging from ultraviolet to near infrared, the linker cleaves and
causes the vesicle to rupture [13, 14]. The synthesis and purification of such linkerderived polymers can be challenging and often the energy required to cleave the linkers
can be quite high and biologically unfeasible.

Previously, our group reported a linker-free polymersome composite system with
tunable sensitivity to light. Polymersomes encapsulating luminal solute (ferritin or
dextran)

and

a

membrane

encapsulated

meso-to-meso

ethyne-bridged

bis[(porphinato)zinc] (PZn2) chromophore exhibited membrane destabilization and
rupture upon exposure to light [15-17]. The luminal solute functioned to stabilize the
inner leaflet of the bilayer membrane, while PZn2 (a low fluorescent quantum yield
chromophore [18]) acted as a local heating agent upon excitation. The resulting
asymmetric membrane stretching due to heating effects during light excitation caused
the vesicles to rupture. A limitation to our previous work was the excitation wavelength
(blue-green light) and mode of light delivery (multi-line confocal lasers). The translation
to a biologically relevant system with our platform would be challenging due to the strong
absorption and scattering of blue-green light by hemoglobin, deoxyhemoglobin, melanin,
and other proteins [19]. In the work presented here, we report an optimization of our
existing platform where we cause light-induced rupture of micron-sized polymersomes
with near infrared light at biologically relevant light doses. We compare the release of a
model small molecule drug (sulforhodamine B) from two different polymersomes
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composed of a soft (PEO14-b-PBD22, denoted OB14.5) and stiffer membrane (PEO30-bPBD46, denoted OB29).

3.3 Materials and Methods
3.3.1 Materials
Poly(ethylene oxide)-poly(butadiene), PEO14-b-PBD22 (OB14.5, MW = 1800
g/mol) and PEO30-b-PBD46 (OB29, MW = 3800 g/mol) were purchased from Polymer
Source (Montreal, Canada). A molecular weight series of Dextran (Leuconostoc
mesenteroides and Leuconostoc spp.), Optiprep, and octyl β-D-glucopyranoside were
purchased from Sigma Aldrich (St. Louis, MO). Methylene chloride (HPLC grade),
phosphate buffered saline (PBS), and sucrose were purchased from Fisher Chemicals
(Pittsburgh, PA). The meso-to-meso ethyne bridged (porphinato) zinc(II) dimer (PZn2,
MW = 2123 g/mol) was synthesized by the Therien lab as previously described [18].

3.3.2 Polymersome preparation
Polymersomes were prepared using thin-film rehydration. 1mM OB polymer
(OB14.5 or OB29) with PZn2 at a molar ratio of 10:1 (polymer:fluorophore) were
dissolved in methylene chloride. 200µL of this solution was deposited on a roughened
Teflon strip and evaporated for 24 hours. Dextran at the desired molecular weight was
dissolved at 5, 10, and 20 mg/mL in 290 mOsm sucrose. Sulfrorhodamine B was also
dissolved in the sucrose solution with dextran at a concentration of 100mM. The
resulting hydration solution was added to the OB-PZn2 composite film and hydrated at
65ºC for 16 hours. Following the hydration period, the films were vortexed for one
minute, which resulted in the spontaneous assembly of NIR emissive polymersomes,
containing PZn2 in the hydrophobic membrane and Dextran and sulforhodamine B in the
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aqueous core. The polymersomes were purified from unencapsulated Dextran and
sulforhodamine B by centrifugation in a step gradient. The top layer contained the
polymersome sample diluted in iso-osmotic PBS and the bottom layer contained a
solution of sucrose and density gradient medium (80% sucrose/20% Optiprep by
volume). The sample was spun at 10,000 RPM for 1 hour at 4ºC. The polymersomes
migrated to the interface of the step gradient and were retrieved with a syringe. The
polymersome sample was dialyzed against iso-osmotic PBS to remove any trace
Dextran, sulforhodamine B, and Optiprep.

3.3.3 Photodestruction of polymersomes and quantification of release
A 690 nm diode laser (Model BWF2-690-1.0-400, B&W TEK Inc.) was used to
illuminate the polymersomes in a well plate and cause photodestruction. The fluence
rate was modulated to 200 mW/cm2 and delivered via a microlens tipped fiber. The total
light dose varied was varied to 100 J/cm2. Post illumination, the released sulforhodamine
B was separated from the polymersomes via centrifugation in Amicon centrifugal filters
(NMWCO 10kDa). The fluorescence of the sulfrorhodamine B (λex = 480 nm, λem = 580
nm) in the filtrate was measured using a Jobin Yvon Fluoromax-4 spectrofluorometer.
100% release was measured by lysing the polymersomes with 30mM octyl β-Dglucopyranoside. The fractional release (𝑓𝑟 ) was calculated using the following formula

𝑓𝑟 =

𝐹 − 𝐹0
𝐹𝑂𝐺𝑃 − 𝐹0

Equation 3.1

where 𝐹𝑂𝐺𝑃 is the fluorescence of the lysed polymersomes, 𝐹 is the fluorescence of the
treated polymersomes, and 𝐹0 is the fluorescence of the untreated sample.
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3.4 Results and Discussion
3.4.1 Polymersome deformation upon illumination
Polymersomes synthesized from OB14.5 polymer were subjected to both
confocal illumination and 690 nm diode illumination to visualize membrane deformation
and rupture (Figure 3-1B-C). OB14.5 polymersomes subjected to confocal illumination
ruptured very quickly since the excitation wavelengths corresponded with the peak PZn2
absorption (Figure 3-1A). Additionally, the laser energy per unit area (fluence rate) was
extremely high because the laser spot size is on the order of hundreds of nanometers1.
We transitioned the illumination to a 690 nm diode laser with a larger spot size (several
centimeters) and illuminated the polymersomes for 250 or 500 seconds at 200 mW/cm2
for a total light dose of 50 and 100 J/cm2, respectively. The 690 nm laser was chosen
because it corresponded to the PZn2 absorption peak in the near infrared. During
illumination, polymersomes underwent shrinkage and rupture and left behind debris,
which can be visualized in Figure 3-3C. We next sought to quantify the rupture of the
polymersomes by determining the release of

a small fluorescent molecule,

sulforhodamine B. The absorption of sulforhodamine B does not interfere with PZn2
absorption (Figure 3-1A).

1

𝑟𝐴𝑖𝑟𝑦 =

1.22𝜆
2 𝑁.𝐴.

=

1.22(488𝑛𝑚)
2(1.3)

= 230 𝑛𝑚
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Figure 3-1: OB14.5 polymersome deformation and rupture. Polymersomes contain 10 mol% PZn2 in the
membrane and 100 kDa dextran at 10 mg/mL in the core. A) Normalized absorbance of PZn 2 within OB14.5
polymersomes and sulforhodamine B (SRB) in PBS. B) Polymersomes were exposed to confocal
illumination (λex = 458, 488, 515, 543, and 633 nm) corresponding to the peaks in PZn 2 absorption. Timelapsed confocal images show an intact polymersome followed by complete rupture. Scale bar = 10 µm and
time stamp is given in seconds. C) Confocal micrographs of polymersomes illuminated with 690 nm diode
2
2
laser at 200 mW/cm for a total light dose of 50 and 100 J/cm . Polymer debris can be seen indicating
polymersome rupture. Scale bar = 100 µm. The purple fluorescence corresponds to PZn2 emission.

3.4.2 Dependence of dextran MW and concentration on SRB release
We investigated the effects of dextran concentration and molecular weight on the
release of sulforhodamine B from the aqueous core of OB14.5 polymersomes (Figure
3-2). Three different molecular weights (10, 40 and 100 kDa) and concentrations (5, 10,
and 20 mg/mL) of dextran were encapsulated within the polymersomes containing 10
mol% PZn2 in the membrane.
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Figure 3-2: Effect of dextran MW and concentration on SRB release from OB14.5 polymersomes.
2
2
Polymersomes were illuminated at 200 mW/cm for a total light dose of 100 J/cm . Dextran at three different
concentrations and molecular weights were encapsulated in the aqueous core of polymersomes containing
10 mol% PZn2 in the membrane. Fractional release was determined by scaling and normalizing SRB
emission between the untreated case (0% release) and after addition of the non-ionic surfactant octyl-β-Dgluopyranoside (OGP, 100% release). Error bars indicate standard deviation. N = 3 for each condition.

A modest SRB release of about 15-20% was observed for 10 and 40 kDa at all
concentrations after treatment with 690 nm at a light dose of 100 J/cm 2. The fractional
release increased to about 35-40% for the OB14.5 polymersomes containing 100 kDa
dextran. Control polymersomes that contained either dextran or PZn2 (but not both) had
negligible release. We found that the key determinant in polymersome rupture was the
molecular weight of the dextran and not the concentration. Larger molecular weight
dextrans are more amphiphilic than smaller dextrans and as such have the ability to
interact with bilayer membranes and lower the membrane elastic modulus [21-23].
Previous work in our lab with OB29 polymersomes has shown that high molecular
weight dextran lowered the membrane elastic modulus of polymersomes compared to
control polymersomes containing no dextran, and that OB29 polymersomes were softer
than the more rigid OB18 polymersomes [16]. We expect this trend to continue and that
OB14.5 polymersomes are softer than OB29 polymersomes.
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3.4.3 Light dose dependence on SRB release from OB14.5 and OB29
polymersomes
From the previous study, we identified that the dextran molecular weight and not
its concentration within the polymersome determined the release from polymersomes.
For subsequent studies, we investigated the light-dose response of OB14.5 and OB29
polymersomes encapsulating 100 kDa dextran at 10 mg/mL with 10 mol% PZn2 in the
membrane (Figure 3-3). After illuminating the samples with a 690 nm laser, we
separated the intact polymersomes from the released SRB and quantified the relative
amount of released SRB using fluorescence.

Figure 3-3: Light-dose dependence on SRB release from OB14.5 and OB29 polymersomes.
Polymersomes synthesized with 100 kDa dextran at 10 mg/mL in the lumen and 10 mol% PZn 2 in the
2
membrane. Polymersomes illuminated with 690 nm laser at 200 mW/cm . A) Representative emission scans
2
of SRB released from OB14.5 polymersomes upon treatment with 0, 10, 25, 50, and 100 J/cm of light.
100% release was determined by adding a non-ionic surfactant, octyl-β-D-gluopyranoside. B) Release
curves of SRB from OB14.5 and OB29 polymersomes after illumination. Error bars indicate standard
deviation. N = 3 for each condition.
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As shown in Figure 3-3A, SRB emission increased as a function of light dose for OB14.5
polymersomes. A similar analysis was conducted for OB29 polymersomes as well. We
scaled and normalized the emission scans to generate release curves as a function of
light dose (Figure 3-3B). OB14.5 polymersomes released more SRB than OB29
polymersomes at all light doses. We expect this to be the case since we calculated the
Ka for OB14.5 polymersomes to be less than the Ka for OB29 polymersomes (i.e.
OB14.5 formed softer membrane). OB29 polymersomes were better able to withstand
the asymmetric stretching that occurred during excitation (and PZn2 heating).

As a control, we measured the solution temperature post illumination to ensure
that drastic fluctuations in temperature were not causing photorelease of SRB from
polymersomes. After 100 J/cm2 of light delivery, the temperature of the polymersome
solution increased by a maximum of 3ºC from room temperature. This result was initially
surprising because theoretical calculations suggest that a system of water initially at
room temperature needs a total of 130 J/cm2 of energy to completely vaporize
(assuming a total mass of 0.05g water, which was our sample volume that was
illuminated). However, this thermodynamic calculation requires an adiabatic system,
which our system was not. The supplied radiative energy was absorbed by the porphyrin
and converted to thermal energy. The net effect was a small increase in solution
temperature and polymersome rupture.

3.5 Conclusion
We showed that giant polymersomes containing a porphyrin dimer (PZn2) in the
hydrophobic membrane and dextran in the aqueous lumen ruptured in response to 690
nm laser illumination. The polymersomes were responsive up to 100 J/cm2 of light
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delivery, after which the release fraction started to plateau. We found that dextran
molecular weight (and not concentration) is a determining factor in the release of
sulforhodamine B from the aqueous lumen of polymersomes.
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4 Light Responsive Nanopolymersomes for the Photodynamic
Therapy of Ovarian Cancer
4.1 Summary
Photodynamic therapy (PDT) requires the administration of a photosensitizer
followed by illumination of diseased tissue with light to produce toxic singlet oxygen.
Many photosensitizers currently being used in PDT are hydrophobic and require a
delivery vehicle to increase their solubility and absorption both in vitro and in vivo. A
standardly used construct is to embed the photosensitizer benzoporphyrin derivative
monoacid A (BPD-MA) into liposomes. Here, we explore an alternative: the
encapsulation and delivery of BPD-MA from a polymersome assembled from
poly(ethylene oxide)–b-poly(butadiene) di-block co-polymer. We studied the intracellular
uptake and toxicity of both the polymersomal and liposomal formulations and found that
the polymersomes produced greater in vitro toxicity despite generating less singlet
oxygen. The polymersomes served to protect BPD-MA from being leached and
associated with serum proteins. In vivo studies showed that while BPD-MA-loaded
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polymersomes and verteporfin had similar biodistribution profiles, the polymersome
formulation performed at par with verteporfin in reducing tumor growth despite being
present in a lower concentration within the tumor.

4.2 Introduction
Photodynamic therapy (PDT) is a clinically approved cancer therapy that can
selectively kill malignant tissue. This therapy has been approved by the FDA for the
palliation or treatment of diseases that include high-grade dysplasia (HGD) associated
with Barrett’s Esophagus (BE), esophageal cancer, and non-small cell lung cancer.
Additionally, clinical trials are being performed to determine the efficacy of PDT for
bladder, mesothelioma, head and neck, pancreatic, and ovarian cancer, among other
malignancies [1-6]. PDT is gaining wider acceptance in the clinic due to its demonstrated
efficacy in treating more widespread superficial diseases, its lack of cumulative toxicities
(and thus repeatability), and its suitability for combination with other therapeutic
approaches [7-10].

PDT requires the administration of a drug (photosensitizer) and illumination of the
diseased tissue [11, 12]. Light absorption by the photosensitizer produces reactive
oxygen species, including singlet oxygen, that damage cellular components. Neither the
photosensitizer nor the light is toxic by itself. The subcellular localization of
photosensitizer is important for phototoxicity because the intracellular diffusion length for
singlet oxygen is about 20 nm, and photodamage occurs very close to the site of the
photosensitizer [13]. Additionally, when performed in vivo, PDT can lead to tumor cell
death through the effects of treatment on host cells and tissues. For example, PDT
damage of the microvasculature can contribute to therapeutic effect by shutting down
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the blood vessels feeding the tumor [14, 15]. Treatment can also elicit an immune
response that is associated with the release of inflammatory cytokines and active
recruitment of leukocytes to the site of photodamage, potentially initiating the
development of anti-tumor immunity [16].

Nanoparticle-based PDT has been studied for a wide variety of photosensitizers
and nanovehicles. Lipid formulations of photosensitizers have received particular
attention because this method of delivery has gained approval from the FDA in the forms
of liposomal doxorubicin and daunorubicin, which were approved in the late 1990s.
Liposomes can provide the necessary hydrophobic environment to solubilize
hydrophobic photosensitizers, and additional modifications such as PEGylation to
increase plasma circulation time and the conjugation of monoclonal antibodies for tumor
targeting can render this class of nanoparticles quite potent [17-19]. Mir et al. integrated
benzoporphyrin derivative monoacid A (BPD-MA) within targeted liposomes and showed
tumor cell killing in an in vitro ovarian cancer model [19]. Polymeric-based nanoparticles
have also been utilized for PDT and offer an advantage over lipids due to the variety of
building blocks and surface functionality [20, 21]. Ding et al. used a non-covalently
encapsulated protoporphyrin IX (PPIX) within polymeric micelles and showed a
photosensitizer-dose response in the killing of lung cancer cells in vitro [22]. dePaula et
al. created biodegradable nanospheres to encapsulate chloroaluminium phthalocyanine
(AlClPc) and showed moderate phototoxicity in human fibroblast culture [23].

Verteporfin (benzoporhyrin derivative monoacid A, BPD-MA) is a secondgeneration lipophilic photosensitizer that produces singlet oxygen at high quantum yield
(ΦΔ = 0.78) [24, 25]. Current FDA-approved indications for verteporfin are limited to the
treatment of subfoveal choroidal neovascularization (CNV) in age-related macular
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degeneration (AMD) [26-28]. Ovarian cancer is the fifth leading cause of cancer deaths
in women and represents another possible indication for PDT mediated by BPD-MA [29].
The work presented here discusses the efficacy and toxicity of BPD-MA encapsulated in
polymersomes in treatment directed toward an ovarian cancer cell line and tumor model.
Polymersomes are self-assembled bilayer vesicles synthesized from diblock copolymers
capable of encapsulating large payloads of both hydrophilic and hydrophobic
compounds [30, 31]. The capacity for carrying large amounts of hydrophobic drugs
comes from hyperthick hydrophobic core of polymersome membranes, which is
conveyed by the large molecular weight of the polymer used to assemble the membrane
[32]. They also confer other advantages over liposomes including increased mechanical
robustness and relative ease of surface functionalization [33-35]. Like liposomes, they
have the capacity to encapsulate both hydrophilic and hydrophobic molecules. Here, we
compare the performance of polymersomes made from poly (ethylene oxide) – b – poly
(butadiene), designated OB14.5, loaded with 40% BPD (OB14.5-40% BPD), with that of
verteporfin in a model for ovarian cancer.

4.3 Materials and Methods
4.3.1 Materials
Reagents were obtained as follows: Singlet oxygen sensor green® (SOSG) from
Life Technologies (Grand Island, NY); Benzoporphyrin derivative monoacid A (BPD-MA)
from U.S. Pharmacopeia (Rockville, MD); VisudyneTM from Valeant Pharmaceuticals
International, Inc. (Bridgewater, NJ); and Poly(butadiene(1,2)addition-b-ethylene oxide)
(PEO(0.60k)-PBD(1.2k), OB14.5) from Polymer Source Inc. (Montreal, Canada). The
meso-to-meso ethyne bridged (porphinato) zinc(II) trimer (PZn3) with a 9-methoxy-1,4,7trioxanonyl substituent on one aryl group and a more hydrophobic 3,3-dimethyl-1-
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butyloxy substituent on the other, was synthesized as previously described [36].
Methylene chloride, methylene blue for colony staining, phosphate buffered saline
(PBS), sodium acetate trihydrate, and sodium chloride were purchased from Fisher
Chemicals (Pittsburgh, PA). Centrifugal filter units were purchased from Millipore
(Billerica, MA).

4.3.2 Cell Line
OVCAR-5 cells (Charles River, NCI Frederick, Frederick, MD) were maintained in
RPMI 1640 media (Invitrogen) with 10% fetal bovine serum (FBS, Sigma) and 1%
Pen/Strep. Media was supplemented with L-glutamine (1%) after three weeks. Cells
were cultured in a humidified incubator at 370C under an atmosphere of 5% CO2.

4.3.3 OB14.5-40% BPD Polymersome Preparation
BPD-loaded polymersomes were prepared via thin film rehydration. Briefly, 1mM
OB14.5 with BPD at a molar ratio of 1:0.4 (polymer:BPD) were dissolved in methylene
chloride. 100 µL of the polymer-drug solution was cast on a roughened 1 cm2 Teflon
surface in a scintillation vial and allowed to dry under vacuum for 24 hours. 1.5mL of
PBS (for in vitro experiments) or 0.9% saline (for in vivo experiments) was added to the
vial, and the composite film was sonicated for 60 minutes to generate nanometer-sized
polymersomes containing BPD at a molar ratio of 40% in the membrane. Polymersomes
were subjected to five cycles of freeze/thaw in liquid N2 and hot water to narrow the size
distribution of polymersomes. The final drug concentration in polymersomes was
measured by UV/Vis absorbance with an extinction coefficient of 0.044 cm-1 (µg/mL)-1 at
690 nm. The polymersome sample was diluted to 20 ng/mL for in vitro experiments. Five
to eight vials were prepared and combined for in vivo experiments. The final
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concentration of 0.1 mg/mL for mice injections was prepared by concentrating the total
volume from five to eight vials in 50 kDa Amicon centrifugation tubes.

4.3.4 Verteporfin Preparation
Visudyne™ (verteporfin for injection) was weighed and hydrated with 1mL of
PBS (for in vitro experiments) or 0.9% saline (for in vivo experiments). The concentration
of active compound (BPD) in verteporfin was measured monthly, and varied from 1.4 –
1.9 mg BPD/100 mg. The active drug concentration was diluted to 20 ng/mL for in vitro
experiments and 0.1 mg/mL for in vivo experiments.

4.3.5 Determination of Singlet Oxygen Production
Singlet oxygen sensor green® (SOSG) was protected from light and stored at 20ºC. Fresh aliquots were prepared before the study. Singlet oxygen production was
determined both in PBS and 5% serum. 180 µL of 1 µM BPD-MA as verteporfin or
OB14.5-40% BPD was added in wells in a 96 well plate in triplicate. 20 µL of a 15 µM
SOSG solution was added to each well. The samples were illuminated at 690 nm with a
fluence rate of 40 mW/cm2. The total delivered light dose was 0, 5, 10, 20, 50, and 100
J/cm2.

4.3.6 Photodynamic Therapy
A 690 nm diode laser (Model BWF2-690-1.0-400, B&W TEK Inc.) was used to
deliver monochromatic light for in vitro and in vivo experiments. For in vitro experiments
(clonogenic assays), the laser spot size was focused to 6 cm via a microlens-tipped
optical fiber and an attenuator was used to modulate the fluence rate to 40 mW/cm2, as
measured by a power meter (LabMaster power meter; Coherent, Auburn, CA). OVCAR-
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5 cells were treated with OB14.5-40% BPD or verteporfin for 12 h in T-75 flasks to allow
for drug internalization. Following the incubation period, cells were washed with Hank’s
buffered saline solution (HBSS), moved to 6 cm dishes, and treated with 0, 5, 10, 15, or
20 J/cm2 of light. For in vivo experiments, mice were injected via tail vein with 1 mg/mL
BPD as either polymersomes or verteporfin. The fluence rate was modulated to 75
mW/cm2 with a spot diameter of 1.1 cm to cover the mouse tumor. The total delivered
light dose was 75 J/cm2.

4.3.7 Clonogenic Assay
OVCAR-5 cells were incubated with OB14.5-40% BPD or verteporfin at an
equivalent BPD concentration of 20 ng/mL in low serum RPMI 1640 media (5% FBS, 1%
Pen/Strep) for 12 hours. Following the incubation period, the cells were washed with
HBSS to remove uninternalized drug. Trypsin (0.05%) was added to detach the cells
from the flask and the cells were counted. The PDT treatment is described above. A
total of 2 x 105 cells were treated in a 6 cm dish with 0, 5, 10, 15 or 20 J/cm2 of 690 nm
light at 40 mW/cm2. Following illumination, cells were plated in 10 cm tissue culture
dishes in RPMI 1640 complete media (10% FBS, 1% Pen/Strep). Cells were plated at
concentrations of 102, 103, 104, or 105 cells per dish depending on the treatment
condition. Dishes were incubated for 10-12 days and removed when the control dishes
(no treatment) formed visible colonies. After removal of the media, a solution of 0.25%
methylene blue (in 30% ethanol) was used to stain and fix the colonies. From plates that
contained 10-300 colonies (a colony defined by 50 or more cells) the surviving fraction
(SF) was defined as follows:


Plating efficiency = number of colonies formed by untreated cells / number of
cells plated
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Surviving fraction = (number of colonies formed by treated cells) / (number of
cells plated * plating efficiency)

4.3.8 Cryogenic Transmission Electron Microscopy
Cryogenic transmission electron microscopy was performed at the Krishna P.
Singh Center for Nanotechnology at the University of Pennsylvania (Philadelphia, PA).
Lacey formvar/carbon grids (Ted Pella) were rinsed with chloroform to dissolve and
remove the formvar template. Grids were carbon coated with a Quorum Q150T ES
carbon coater (Quorum Technologies, UK) and cleaned on both sides with
hydrogen/oxygen plasma for 15 seconds using Solarus Advanced Plasma System 950
(Gatan, Pleasanton, CA). 2 µL of either the polymersome sample or verteporfin was
deposited on the lacey/formvar grid and inserted into a cryoplunger (Gatan Cp3, Gatan).
The sample was blotted by hand with filter paper and plunged into liquid ethane.
Samples were transferred to a Gatan CT3500TR cryoholder. The cryoholder was
immediately inserted into a JEOL 2100 HRTEM (JEOL, Tokyo, Japan) operating at 200
kV. Images were taken with an Orius SC200 digital camera.

4.3.9 In Vitro Cellular Internalization and Serum Binding
OVCAR-5 cells were separately incubated with 20 ng/mL verteporfin and
OB14.5-40% BPD polymersomes for predefined lengths of time (15 minutes, 3 hours, 6
hours, 12 hours, and 24 hours) in low serum RPMI 1640 media (5% FBS, 1% Pen/Strep)
in 6 well plates. After the indicated incubation period, the cells were rinsed three times
with RPMI 1640 media containing no serum to remove uninternalized drug. After the
washing step, cells were removed from the wells with 0.05% Trypsin. A small aliquot
was used to determine the cell density using a coulter counter. The remaining cells were
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centrifuged to a pellet (1500 RPM, 5 minutes), and resuspended in 0.5 mL SOLVABLETM
(Perkin Elmer) to completely digest the cells. The cells were digested for 4 hours at 50ºC
in the dark in amber glass vials. After the digestion period, 0.5 mL of MilliQ water at
room temperature was added to dilute and cool the tissue sample. 0.6 mL of the total
volume was assayed for BPD-MA content using a Fluoromax-4 spectrophotometer
(Jobin Yvon) (λex = 435 nm, λem = 630 – 750 nm). The peak fluorescence emission at
690 nm was used to determine the concentration of BPD-MA in solution. The
concentration of BPD-MA in solution was determined from a calibration curve. For serum
binding experiments, verteporfin or OB14.5-40% BPD polymersomes were incubated at
20 ng/mL BPD-MA with 5% calf serum at 37°C for predefined lengths of time (15 min, 3
h, 12 h, and 24 h) and kept in the dark. After the incubation period was complete, the
nanoparticles were separated from the serum protein using an amicon filter unit (MWCO
1000kDa). The BPD content was measured via fluorescence at its emission peak of 690
nm. As a control, verteporfin and OB14.5-40% BPD polymersomes were incubated with
PBS.

4.3.10 In Vivo Biodistribution
4.3.10.1 Live-Animal Longitudinal Study
Prior to drug administration, OVCAR-5 cells were injected subcutaneously on
both the left and right shoulders of female Athymic nude mice (30 µL per injection at a
density of 2.67 x 108 cells/mL). Mice were maintained on a chlorophyll-free diet (Harlan
Laboratories) 10 days prior to imaging. After the tumors reached approximately 100 mm 3
in size, mice were injected via tail-vein with the following formulations of drug or
fluorescent labels: verteporfin, OB14.5-40% BPD, OB14.5-40% BPD/2.5% PZn3 (duallabeled polymersome), and OB14.5-2.5% PZn3. The BPD concentration was maintained
at 0.1 mg/mL for the formulations containing photosensitizer. The molar ratio of
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BPD:PZn3 in the dual-encapsulated polymersome was kept at 16:1. At predefined time
points post tail-vein injections (15 minutes, 1 hour, 3 hours, 8 hours, and 24 h),
anesthetized mice (inhalation of isoflurane) were imaged on the LI-COR Pearl® Impulse
Small Animal Imaging System (LI-COR Biosystems). BPD signal was captured in the
700 channel (λex = 685 nm, λem = 720 nm) and PZn3 signal was captured in the 800
channel (λex = 785 nm, λem = 820 nm). A white-light image was captured in the white
channel. The imager resolution was set to 85 µm. Mice were imaged on the left and right
sides to detect signal from the left and right tumors, and the ventral position to detect
signal from the abdominal organs. Images were analyzed with the Pearl Impulse
Software by drawing ROIs over the tumor, upper abdomen, and lower abdomen and
recording the mean signal per area.

4.3.10.2 End-Point Organ Biodistribution
Prior to drug administration, OVCAR-5 cells were injected subcutaneously on
both the left and right shoulders of female Athymic nude mice (30 µL per injection at a
density of 2.67 x 108 cells/mL). After the tumors reached approximately 100 mm3 in
size, mice were injected with equivalent dose of verteporfin or OB14.5-40% BPD at 0.1
mg/mL BPD via tail vein injection. At predefined time points (15 min, 3 h, 6 h, 16 h, and
24 h), the mice were anesthetized with an intraperitoneal injection of ketamine/xylazene.
Whole blood was collected by cardiac puncture in sodium heparin-coated syringes.
After confirmation of death, tumor, liver, intestines, and spleen were harvested for
analysis of BPD-MA. All organs were stored in cryo vials at -80ºC. Plasma was isolated
as follows: whole blood was collected in 1 mL Eppendorf tubes and centrifuged at 1000
RPM for 15 min at 22ºC. The top layer, which included plasma and some white blood
cells, was carefully decanted and spun a second time at the same conditions as above.
The purified plasma was collected and stored at -80 ºC.
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During processing for spectrofluorometric analysis, tweezers were used to
squeeze-out and remove any remaining food in the GI tract (intestines isolation). 30 – 50
mg of tissue was weighed in 10 mm dishes and minced with surgical scissors. Minced
tissue was placed into glass amber vials and 0.5 mL of SOLVABLETM (Perkin Elmer,
Waltham, MA) was added to digest the tissue. Digestion took place for 4 hours at 50ºC
in the dark. After the digestion period, 0.5 mL of MilliQ water at room temperature was
added to dilute and cool the tissue sample. 0.6 mL of the total volume was assayed for
BPD-MA content using a Fluoromax-4 spectrophotometer (Jobin Yvon) (λex = 435 nm,
λem = 630 – 750 nm). The peak fluorescence emission at 690 nm was used to determine
the concentration of BPD-MA in solution. Separately, calibration curves were generated
to relate fluorescence emission at 690 nm to drug concentration for the organs of
interest by adding known concentrations of verteporfin or OB14.5-40% BPD to tissue
harvested from mice that received no drug treatment.

4.4 Results and Discussion
BPD-MA is a potent second generation hydrophilic photosensitizer [24]. Because
of its poor solubility in aqueous environments, BPD-MA was formulated in a liposomal
association and sold as VisudyneTM (verteporfin for injection). We have tested the
encapsulation of BPD-MA in the hydrophobic membrane of polymersomes as an
alternative delivery vehicle with the potential for high BPD-MA loading. A schematic of
singlet oxygen generation by polymersome-encapsulated BPD-MA is presented in
Figure 4-1.
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Figure 4-1: Polymersome delivery system. (a) Cartoon illustrating the encapsulation of BPD-MA in the
hydrophobic core of the membrane of a polymersome. Excitation with 690 nm light causes BPD-MA to
3
1
covert nearby ground-state triplet oxygen ( O2) into cytotoxic singlet oxygen ( O2). (b) Chemical structure of
BPD-MA. (c) Chemical structure of the polymer OB14.5.

4.4.1 Nanoparticle characterization
Three different nanoparticle formulations were synthesized to understand the
delivery and toxicity of the hydrophobic photosensitizer BPD-MA both in vitro and in vivo.
VisudyneTM (verteporfin for injection) is a liposomal formulation of BPD-MA with an active
drug fraction at 1.4 – 1.9 wt%. We developed a novel formulation of BPD-MA by
encapsulating it in the hydrophobic membrane of OB14.5 polymersomes at a molar ratio
of 1:0.4 (polymer:BPD), with an effective weight fraction of 16 wt% BPD. We also
assembled OB14.5 polymersomes with a hydrophobic NIR emissive porphyrin trimer
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(PZn3) [32, 36] at a molar ratio of 1:0.025 (polymer:PZn3), as well as dual-labeled
OB14.5 polymersomes with both BPD and PZn3 at molar ratios of 0.4 and 0.025,
respectively, for in vivo polymersome tracking.

The structure of the nanoparticles was confirmed with dynamic light scattering
(DLS) and cryogenic transmission electron microscopy (cryo-TEM) (Figure 4-2a and
Figure 4-2b, respectively). DLS shows that the average hydrodynamic diameters for all
three polymersome formulations (BPD only, PZn3 only, and dual BPD/PZn3) are around
100 nm. The DLS results for verteporfin show an extremely polydisperse population
ranging in size from 10 – 1000 nm. We imaged the structure of verteporfin and OB14.540% BPD via cryo-TEM. Verteporfin is a liposomal formulation of BPD and consisted of
a heterogenous population of micelles, sheets, and vesicles. OB14.5-40% BPD
polymersomes, on the other hand, were predominantly spherical vesicles with a
narrower size distribution from 30 – 200 nm. Thus the polymersomes offer the
advantage that size and shape can be precisely controlled. Size of nanoparticles plays
an important role in their in vivo efficacy. Work done by Anraku and coworkers measured
the residence time of polymersomes of various sizes in the plasma, tumor, liver, and
spleen of mice and found that the optimal polymersome size is between 100 – 150 nm
for extended plasma circulation (circulation half-life of 23 hours) [37].
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Figure 4-2: Nanoparticle characterization. (a) Dynamic light scattering showing the hydrodynamic
diameter of polymersomes containing BPD, PZn3, or both, and verteporfin. (b) Cryo-TEM micrographs of
verteporfin and OB14.5-40% BPD. (c) UV/Vis absorbance spectra of nanoparticles containing BPD, PZn3, or
both, and verteporfin.

The encapsulation of the drug was confirmed via UV/vis absorbance spectroscopy
(Figure 4-2c). BPD and PZn3 feature NIR absorbance bands centered respectively at
690 and 794 nm.
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4.4.2 In situ Singlet Oxygen Detection
The phototoxicity from cell-localized verteporfin and OB14.5-40% BPD is a direct
consequence of the ability of these nanoparticles to generate singlet oxygen. In order to
quantify the singlet oxygen production from these nanoparticles, we utilized Singlet
Oxygen Sensor GreenTM (SOSG) that captures singlet oxygen once it is released into
solution and fluoresces.

Figure 4-3: SOSG detection of Singlet Oxygen. Singlet oxygen was generated by irradiating BPD
2
nanoparticles at 690 nm in the presence of SOSG at a fluence rate of 40 mW/cm . (a) Detection of singlet
oxygen formation by verteporfin and OB14.5-40% BPD at the same concentration of BPD (1µM). (b)
Normalized SOSG signal per n vesicles from OB14.5-40% BPD and OB14.5-10% BPD.

The assay can detect singlet oxygen only if it is able to diffuse out of the hydrophobic
membrane of the polymersomes and into solution. We detected a greater concentration
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of singlet oxygen from verteporfin than OB14.5-40% BPD at all light doses, potentially
due to the loose association of BPD with the liposome and the protection of BPD by the
hyperthick polymersome membrane. The high BPD-MA loading within the polymersome
membrane may have also played a role in the lower singlet oxygen concentrations
determined for OB14.5-40% BPD relative to that measured for BPD liposomes. It is also
possible that the singlet oxygen that generated in the polymersome membrane diffused
into the inner aqueous lumen where SOSG is not present. This could potentially reduce
the SOSG signal.

We also compared the singlet oxygen production from polymersomes loaded
with 10% and 40% BPD in the membrane by normalizing to the vesicle number. In order
to equate the BPD concentration, the 10% BPD polymersomes must be present in four
times the number as the 40% BPD polymersomes. After normalizing by vesicle number
(Figure 4-3b), OB14.5-40% BPD did produce greater singlet oxygen than OB14.5-10%
BPD, as was expected. However, we did not observe a proportional difference in singlet
oxygen production between polymersomes loaded with 10% and 40% BPD, possibly
due to singlet oxygen quenching. Nevertheless, we chose OB14.5-40% BPD
polymersomes for in vitro and in vivo studies with the objective of killing OVCAR-5 cells
due to its higher production of singlet oxygen per vesicle.

4.4.3 In vitro Cellular Internalization and Serum Binding
Initial in vitro studies were conducted to assess BPD internalization into OVCAR5 cells after polymersome versus liposome (i.e. verteporfin) delivery (Figure 4-4a).
OVCAR-5 cells were incubated with 20 ng/mL of BPD as either verteporfin or OB14.540% BPD polymersomes in low serum (5% FBS) RPMI 1640 media for predefined
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lengths of time (15 minutes, 3 hours, 12 hours, and 24 hours). The concentration of drug
was measured using a spectrofluorometer and normalized to the total cell count. The
amount of BPD per cell increased as a function of time for both verteporfin and the
polymersomal formulation and leveled off after 12 hours. The total drug content was
statistically greater for polymersomes than verteporfin after 12 and 24 hours of
incubation.

Figure 4-4: BPD uptake and serum binding. (a) BPD uptake per cell as a function of incubation time. * p =
0.005 and ** p = 0.03. (b) BPD association to serum proteins as a function of incubation time. Incubation
with PBS (no serum) had negligible signal (0.032 for OB14.5-40% BPD and 0.034 for verteporfin). ◦ p =
0.02, ◦◦ p = 0.006, and ◦◦◦ p = 0.002. p-values were determined from a two-tailed student’s t-test with α =
0.05. Error bars indicate standard deviation.

Because BPD-MA is a hydrophobic molecule and is known to partition into LDL
proteins in circulation [38], we next explored the serum association of BPD-MA in
verteporfin and OB14.5-40% BPD polymersomes (Figure 4-4b). Verteporfin and OB14.540% BPD polymersomes were incubated in PBS containing 5% FBS (low serum to
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match the uptake study) for predefined lengths of time. A high MWCO membrane was
used to separate the serum proteins from the nanoparticles and the presence of BPD
was measured in the serum-containing filtrate. As shown in Figure 4-4b, BPD-MA
partitions into serum proteins. We ensured that the membranes were very selective to
the serum proteins – no verteporfin or polymersomes went through. As an additional
control, verteporfin and polymersomes were incubated in PBS without any serum. BPDMA did not leach into the surrounding buffer and remained associated with the
nanoparticles. The decreased BPD fluorescence for serum proteins that were incubated
with polymersomes suggested that the polymersomes were better able to protect the
photosensitizer against serum leaching. Thus, the fraction of drug that is serum bound is
much less for polymersomes than verteporfin. Based on differences in BPD association
with serum at 12 h after incubation in verteporfin versus OB14.5-40%, together with the
increased cell uptake of polymersome-delivered BPD at this time point, a 12 hour drug
incubation period was chosen for further in vitro PDT studies.

4.4.4 In vitro PDT of OVCAR-5 Cells
OVCAR-5 cells were treated with 20 ng/mL of BPD for 12 hours as either
verteporfin or OB14.5-40% BPD, followed by illumination at 690 nm. Cell survival
decreased as a function of increasing light dose for both formulations (Figure 4-5a), thus
the greatest difference in cytotoxic effect was detected at the highest light dose of 20
J/cm2. At this dose, PDT led to a surviving fraction of 0.008 for verteporfin and 0.002 for
OB14.5-40% BPD (a 4-fold difference in survival). Controls with drug only and light only
(20 J/cm2) showed no toxicity when compared to the case without treatment (surviving
fractions of 1.05 and 0.98, respectively).
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Figure 4-5: OVCAR-5 Surviving Fraction after PDT. (a) OVCAR-5 cells were incubated with 20 ng/mL of
BPD-MA as either verteporfin or OB14.5-40% BPD polymersomes for 12 hours. The light dose was varied
2
by modulating the illumination time. The fluence rate was held constant at 40 mW/cm . * p = 0.014, ** p =
0.036, *** p = 0.003. (b) OVCAR-5 cells were incubated with 20 ng/mL of BPD-MA for 12 hours as OB14.52
10% BPD or OB14.5-40% BPD. ◦ p = 0.0007. The light dose in (b) was kept constant at 20 J/cm with a
2
fluence rate of 40 mW/cm . p-values determined from single factor ANOVA with the level of significance, α =
0.05. Error bars represent standard deviation.

Despite the lower measured singlet oxygen production by OB14.5-40% BPD compared
to verteporfin (as shown in Figure 4-3), the polymersomes produced greater
phototoxicity than verteporfin at all light doses. This effect could be the result of an
increase in cellular uptake of BPD when delivered by polymersomes (see Figure 4-4a).
Also, the greater toxicity of polymersome-mediated PDT could be related to high local
concentrations of singlet oxygen that are produced by OB14.5-40% BPD. To test the
latter hypothesis, we treated OVCAR-5 cells with equal BPD concentration (20 ng/mL) of
OB14.5 polymersomes loaded with 10% or 40% BPD in the membrane. Results showed
that a lower molar loading of BPD in the polymersome membrane (10% vs. 40%)
produced very little phototoxicity even though the total BPD concentration was identical
(Figure 4-5b). This suggests that highly localized concentrations of BPD as can be
delivered by polymersomes can significantly benefit cytotoxicity, although this is
associated with the caveat that high loading can promote inefficiencies in singlet oxygen
production, perhaps due to quenching.
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4.4.5 In Vivo Biodistribution
We investigated the in vivo biodistribution of verteporfin and OB14.5-40% BPD
polymersomes in nude Athymic female mice first via a semi-quantitative longitudinal
imaging study using an NIR imager, and second with a quantitative end-point assay
using a spectrofluorometer.

For the longitudinal imaging study, BPD-MA was injected via tail vein at a dose of
1 mg/kg as verteporfin or OB14.5-40% BPD. The fluorescence of BPD-MA was
monitored in the 700 channel of the LI-COR Pearl® Impulse Small Animal Imaging
System in the tumor (one each on left and right shoulders of the animal), as well as in
the upper and lower abdomen, which corresponded to signal from mostly the liver and
intestines, respectively. Based on our previous results showing that BPD-MA partitioned
into lipophilic environments such as serum proteins (Figure 4-4), we also injected the
mice with polymersomes encapsulating PZn3 to track the polymersomes themselves.
PZn3 is a large and hydrophobic molecule that remains associated with the
polymersome membrane for a prolonged length of time compared to BPD. OB14.5-40%
BPD/2.5% PZn3 (dual-labeled) and OB14.5-2.5% PZn3 (singly-labeled) polymersomes
were injected separately to track the separation of photosensitizer from polymersomes
and polymersome location, respectively, in the 800 channel of the Pearl®. PZn3 has
previously been used for the in vivo tracking of dendritic cells, and an in vitro and in vivo
study of polymersomes localization [32, 34, 35, 39, 40].
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Figure 4-6: Longitudinal imaging of polymersomes formulated as OB14.5-40% BPD and/or OB14.52.5% PZn3. (a) Mice received dual-labeled OB14.5-40% BPD/2.5% PZn3 polymersomes. Left column shows
the left side of a mouse (arrow points to left tumor) and the right column shows the ventral side of the
mouse. Emission has been pseudo-colored red (700 channel for BPD-MA) and green (800 channel for
PZn3). (b) In mice that received verteporfin, OB14.5-40% BPD, or OB14.5-2.5% PZn3, ROIs were drawn
over the tumors, upper abdomen and lower abdomen to measure the signal intensity per pixel (n = 2 – 3
mice per condition). Error bars indicate standard deviation. Intensity values were normalized within each
mouse to the values measured at 15 minutes after drug injection.

Figure 4-6 shows the time-course of drug distribution in a mouse given duallabeled polymersomes. At early times (15 minutes and 1 hour) after injection, both BPDMA and the polymersome can be seen in the liver (yellow colocalization in the liver).
After 1 hour, BPD-MA started to accumulate in the lower abdomen and was present in
large amounts in the intestines (3 hours). After 8 hours, the lower abdomen was cleared
of BPD-MA altogether. In animals that received verteporfin, OB14.5-40%, or BPD/2.5%
PZn3, we quantified the signal intensity from the left and right tumors, upper abdomen,
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and lower abdomen (Figure 4-6b). Based on these results, BPD-MA in verteporfin and
OB14.5-40% BPD has a similar biodistribution with the exception of a delayed clearance
of OB14.5-40% BPD from the upper abdomen (see 1 h timepoint). In tumors, it appears
that BPD begins to be cleared at times after 3 h for both the liposomal and
polymersomal formulations. In contrast, the PZn3 signal is very consistently seen in the
tumor and lower abdomen, indicating that the polymersomes are staying in these
locations. There is moderate clearance from the upper abdomen, but the clearance rate
is much slower for the polymersomes than for the BPD.

The imaging study provided a unique insight - that both the photosensitizer and
polymersomes were reaching the tumor, and that the polymersomes were present for
long times within the mice. Using an ex vivo spectrofluorimetric assay, the biodistribution
of BPD-MA after liposome vs. polymersome delivery was studied in greater detail for
each organ. Mice were injected with verteporfin or OB14.5-40% BPD at a dose of 1
mg/kg. After predefined time points (15 minutes, 3 hours, 8 hours, 16 hours, and 24
hours), blood was collected via cardiac puncture, then tumor, liver, spleen, and
intestines were harvested from the euthanized animals. The aforementioned organs
were analyzed for BPD-MA content by digesting these organs in a strong base and
measuring the fluorescence of BPD-MA in the solubilized tissue (Figure 4-7). OB14.540% BPD was more slowly taken up into the tumor than verteporfin as indicated by a
significantly lower BPD-MA concentration at 3 h after injection of the polymersomes.
Given the extremely similar plasma concentrations of drug for the formulations, it is likely
that the delayed tumor uptake of BPD with polymersomes compared to verteporfin is
due to the increased size of the polymersomes. Once present in the tumor, the BPD-MA
concentration remained fairly equal between the two formulations. In the abdominal
organs, the intestines (and to insignificant levels, the liver) were noted to have high BPD67

MA uptake at 15 min after administration of polymersomes, but this cleared to levels
equivalent to liposome-delivered BPD at 3 h post-injection. At the longer time points of
16 and 24 h, the intestines, liver, and spleen had a small but significantly increased
concentration of BPD-MA after administration of polymersomes compared to that
resulting from liposome delivery of BPD. This is consistent with the longer retention of
polymersomes in the upper and lower abdomen by in vivo imaging. Enhanced retention
in abdominal organs could be related to polymersome interaction with immune cells such
as macrophages due to their larger size.
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Figure 4-7: Biodistribution of BPD-MA as delivered by verteporfin and OB14.5-40% BPD. At the
indicated time points after injection, BPD-MA content was measured in the respective organs
spectrophotometrically and calibrated to yield a concentration. Mice were injected with an equivalent dose of
1 mg/kg BPD-MA as verteporfin or OB14.5-40% BPD. * p < 0.05 as determined from single factor ANOVA
with the level of significance, α = 0.05. Error bars represent standard deviation.
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4.4.6 In Vivo Response of OVCAR-5 Tumors
Lastly, the effectiveness of PDT mediated by OB14.5-40% BPD polymersomes
was tested in OVCAR-5 tumor xenografts. Once tumors reached approximately 50 mm3,
mice were injected with an equivalent dose of 1 mg/kg BPD-MA as either verteporfin or
polymersome via tail vein. In oncology studies, BPD-PDT is employed with a 3 h drug
incubation to cause tumor cell damage, so we chose a 3 h interval before illuminating
the tumors with 690 nm light [41, 42]. Tumors were treated with a fluence rate of 75
mW/cm2 light for a total light dose of 75 J/cm2. We monitored tumor growth for 20 days
after PDT. Tumor volumes were determined as follows:

𝑉=

𝜋𝐿𝑊 2
6

Equation 1

where 𝐿 and 𝑊are the length and width of the tumor, respectively, and 𝐿 > 𝑊. Mice
were sacrificed if the tumor volume exceeded 400 mm3.

The tumors of mice that received either verteporfin or OB14.5-40% BPD, but no
light, grew at a similar rate as those that received no light and no drug treatment (Figure
4-8a). Moreover, animals that received light, but no drug (Figure 4-8b plot of “no
treatment”) also grew at a similar rate to the other controls. In contrast, mice that
received PDT (75 J/cm2 of 690 nm light) of their tumors (Figure 4-8b) showed a reduced
tumor growth rate compared to all of the control groups.
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Figure 4-8: PDT response of OVCAR-5 tumors. Nude athymic female mice were treated with saline (no
treatment), OB14.5-40% BPD, or verteporfin at a dose of 1 mg/kg BPD. (a) The control groups received no
2
light treatment. Each condition had three mice. (b) The light-treated group received 75 J/cm of light at a
2
fluence rate of 75 mW/cm . The no treatment group had three mice, whereas the OB14.5-40% BPD and
verteporfin group each had five mice. Error bars are standard error of the mean.

While the tumor response was similar for OB14.5-40% BPD and verteporfin, it
should be noted that the concentration of BPD-MA in the tumor is a factor of 2 lower for
the polymersomes (see 3 h time point on Figure 4-7). Thus, the OB14.5-40% BPD
polymersomes provided equal phototoxicity with a lower dose of BPD than that delivered
by verteporfin.

4.5 Conclusion
In summary, the second generation photosensitizer benzoporphyrin derivative
monoacid A (BPD-MA) was encapsulated in the hydrophobic membrane of

71

polymersomes synthesized from the diblock copolymer, OB14.5 (PEO14-PBD22). The
efficacy of this photosensitizer formulation was compared to an existing liposomal
formulation, verteporfin. OB14.5-40% BPD was more potent at killing OVCAR-5 cells
than verteporfin in vitro as determined from clonogenic assays. The polymersomes
served as a protection against serum binding, thereby increasing the concentration of
free BPD that was able to produce phototoxicity. In vivo, OB14.5-40% BPD
polymersomes and verteporfin had similar biodistribution profiles. There was a lag in
BPD-MA accumulation in the tumor at short times (3 h). Despite having a lower
concentration in the tumor at 3 h, the polymersome formulation performed on par with
verteporfin in studies of tumor response to PDT.
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5 A Hydrodynamic Model of the SizedBased Separation of Polymersomes
Using a Deterministic Lateral
Displacement Microfluidic Device

5.1 Summary
We developed a hydrodynamic, forced-based computational model to understand
the fractionation of polymersomes in a DLD microfluidic device. We found that the key
parameter in determining the separation between two particles is the strength of the
attraction between the cylindrical post and spherical polymersome. We developed a
microfluidic DLD device synthesized from photolithographic techniques to experimentally
separate polymersomes of known sizes. Using this model, we can correctly predict the
fractionation of two polymersomes of different sizes (46 and 58 µm) in a DLD device.
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5.2 Introduction
Particle suspensions have traditionally been fractionated by size using
chromatographic techniques. In this separation technology [1], porous beads are packed
in a column and the particle suspension is driven through the stationary phase via a
pressure gradient. Particles that are smaller than the pore size can travel through the
beads via the tortuous pores, whereas larger particles travel through the void space
created from the bead packing. The resulting fractionation occurs because of the sizedependent path length taken by particles. A disadvantage to this method of fractionation
is the “zone broadening” effect which stems from the fact that two particles of the same
size may take two different paths: one longer and one shorter.

The development of microfluidic devices for particle separation and fractionation is
an

interesting

approach

that

combines

hydrodynamics

with

chromatography.

Deterministic lateral displacement (DLD) devices have been used to separate a wide
range of particle sizes particles with submicron resolution [2, 3]. DLD devices utilize
laminar flow through a periodic array of micron-sized obstacles that are rotated by a
small angle with respect to the direction of flow. Particles that are larger than a critical
size are “bumped” by the obstacles and are unable to cross-over into different lanes,
whereas particles smaller than the critical size “zig-zag” through the device separating
themselves from the larger particles.

Theoretical approaches have been developed to understand the relationship
between device geometry and particle separation [4-6]. In these approaches, particles
follow streamlines until they interact with a post. Larger particles are unable to access
streamlines that are close to the post due to steric hindrance effects and as such are
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bumped by the posts. Smaller particles can travel along streamlines closer to the posts
and can “zig-zag” between posts and migrate down the device at a different trajectory
from larger particles. These approaches, however, do not take into account the vast
majority of forces exerted on the particle by the fluid and posts and as such are unable
to capture the physical motion of particle trajectories.

Frechette and Drazer used a Stokesian Dynamics approach to understand particle
trajectories in DLD devices [7]. Their model looked at the dynamics of a non-Brownian
sphere suspended in a stationary fluid subject to a constant external force and a short
range repulsive interaction. Simulations showed that particles subjected to varying
forcing angles separated themselves based on size. The key difference between the
simulations performed by Frechette and Drazer and the work done here is the inclusion
of non-constant forces that are position dependent. Here we include non-constant
hydrodynamic forces, torques, and van der Waals and steric repulsive forces that are
coupled together via the grand mobility matrix.

5.3 Materials and Methods
5.3.1 Materials
Poly(ethylene oxide)-poly(butadiene), PEO30-b-PBD46 (OB29, MW = 3800 g/mol)
was purchased from Polymer Source (Montreal, Canada). Bovine serum albumin (BSA)
and Pluronic F-127 were purchased from Sigma. Sylgard 184 silicone elastomer base
and curing agent were purchased from Dow-Corning. PBS was purchased from Fisher.
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5.3.2 Microfluidic Vesicle Preparation
Micron-sized vesicles were prepared via a double emulsion technique using a
glass capillary system as described previously [8-11]. The inner aqueous phase
consisted of a solution of 290 mOsm sucrose. The middle organic phase consisted of a
solution of 1 mg/mL OB29 in a mixture of chloroform and toluene (28:72 v/v). The outer
phase consisted of 290 mOsm phosphate buffered saline (PBS) containing 1wt% BSA.
The three solutions were cofocused into a single immiscible stream to generate double
emulsions. These emulsions were collected in 2 mL of PBS in a 20 mL scintillation vial.
The vials were loosely capped and placed on a gentle rocker for 1-2 weeks to allow for
the organic layer to evaporate. The inner flow rate was maintained at 1.5 mL/hr, the
middle flow rate at 7 mL/hr, and the outer flow rate was varied from 20-50 mL/hr to
generate vesicles of various sizes.

5.3.3 Microfluidic Mask Design
The photomask was designed using AutoSketch®. The cylindrical posts are 100
µm in diameter with an edge-to-edge spacing of 60 µm and grid rotation of 8º.

5.3.4 Microfluidic Chamber Preparation
The deterministic lateral displacement device was fabricated by replica molding
on a patterned silicon wafer as the master and polydimethylsiloxane (PDMS) as the
polymer. The master was fabricated by spinning a layer of negative photoresist (KMPR
1050,MicroChem Corp., Brookline, MA) with a thickness of 88 µm onto a smooth silicon
wafer, followed by a ramped soft bake period (65ºC to 115ºC at a rate of 15ºC every two
minutes), and a continuous soft bake period at 115ºC for 15 minutes. The KMPR-coated
wafers were exposed to UV light at a dose of 1520 mJ/cm2 using a contact mask aligner,
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and post baked for seven minutes at 105ºC. The exposed wafer was developed with SU8 developer solution for 10 minutes, followed by an isopropanol rinse and drying. The
device was fabricated by pouring PDMS (PDMS:curing agent 10:1 by weight) over the
master and curing the elastomer for 12 hours at 65ºC. The device was cut out and
separated from the master. Holes were punched out for the inlets and outlets with a flattip stainless steel 20G needle. The PDMS device was plasma bonded to a glass cover
slip.

5.3.5 Microfluidic Chamber Operation
Polymersome and PBS were loaded into one 3 cc and two 10 cc syringes,
respectively. Polymersomes were introduced into the device via a syringe pump
operating at a flow rate of 100 µL/hr. PBS was introduced into the left and right inlet
channels using a second syringe pump operating at a flow rate of 1.5 mL/hr. These flow
rates ensured laminarity in the microfluidic device.

5.3.6 Determination of Forces
We calculated the external forces exerted on the polymersomes by the fluid and
cylindrical posts. Here we specifically considered the shear force exerted on the
polymersome by the fluid, the torque exerted on the polymersome by the fluid due to the
cylindrical posts, the van der Waals force between the polymersome and the posts, and
the steric stabilization between the polymersome and posts. Our computational model
assumed a two dimensional Stoke’s flow in the microfluidic device with negligible
diffusion effects (𝑃𝑒 ≫ 1). Additionally, we ignored top and bottom edge effects in the
calculations of particle trajectories. With these assumptions, we applied a streamline
solution to determine the fluid velocity everywhere in the device.
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Table 5-1: Definition of parameters in the computational model

Parameter

Definition

𝑎

Polymersome radius, 𝜇𝑚

𝜇

Water viscosity, 𝑁 ∙ 𝑠 ∙ 𝜇𝑚−2

𝐹𝑖
𝑓𝑙𝑢𝑖𝑑
𝑣𝑖

Shear force on polymersome (𝑖 = 𝑥, 𝑦), 𝑁
Fluid velocity (𝑖 = 𝑥, 𝑦), 𝜇 ∙ 𝑠 −1

𝑈

Uniform fluid velocity, 𝜇 ∙ 𝑠 −1

𝑅

Post radius, 𝜇𝑚

𝑑𝐺

Differential torque from post, 𝑁 ∙ 𝜇𝑚

𝜏𝑟𝜃

Viscous stress, 𝑁 ∙ 𝜇𝑚−2

𝐻

Hamaker constant, 𝐽

2ℎ

Polymersome to post center to center distance, 𝜇𝑚

𝛾

Compressibility of PEG brush, 𝑁

𝑠

Polymersome to post edge to edge distance, 𝜇𝑚

𝜏

Thickness of PEG brush, 𝜇𝑚

Given the fluid velocity, the shear force on the polymersome was determined by invoking
Stoke’s Law,

𝑓𝑙𝑢𝑖𝑑

𝐹𝑥,𝑦 = 6𝜋𝜇𝑎𝑣𝑥,𝑦

Equation 5.1

The expressions for the fluid velocities are given in the Appendix. In addition to the shear
exerted on the polymersome by the fluid, the fluid flow also introduced a torque on the
particles because the fluid is traveling at a slower velocity near the posts. We can once
again take advantage of the streamline solution to the fluid flow field and determine the
viscous stress on the polymersome. The expression for the differential torque on a
polymersome due to one post is,
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𝑑𝐺 = 𝜏𝑟𝜃 ∙ 𝑎 sin 𝜙 𝑑𝑆

Equation 5.2

We can then integrate all of the differential torque components from the posts and add
them together to obtain the final expression for the torque on the polymersome. The
detailed calculations are presented in the Appendix.

The two nonspecific interactions considered in this model were van der Waals
and steric stabilization interactions. We approximated the interaction between the
spherical polymersome and cylindrical post as a sphere-sphere interaction, where the
expression for the van der Waals force has been determined by Parsegian [12],

𝐹𝑣𝑑𝑊 = −

32𝐻
𝑎3 𝑅 3 2ℎ
3 (4ℎ2 − (𝑎 + 𝑅)2 )2 (4ℎ2 − (𝑎 − 𝑅)2 )2

Equation 5.3

The steric stabilization force is a well-known force in colloidal science [13]. It can be
used to describe interactions between polymer-coated particles, such as cell-cell
interactions in biology, or in our case, polymersome-post interactions. When two
polymer-coated objects come close together, the polymer brushes on the surface
compress and exclude the solvent. The resulting repulsive potential as described by
Bell, Dembo, and Bongrand [14] can be represented as,

𝛾
Γ(𝑠) = 𝑒 −𝑠/𝜏
𝑠
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Equation 5.4

The repulsive force per unit area is simply the negative gradient of the potential with
respect to separation distance. Invoking the Langbein approximation to estimate the
interaction area between the polymersome and the post, the total repulsive force due to
one post is,
1
1
𝐹𝑟 = 2𝜋𝑅𝛾𝑠 ( + 2 ) 𝑒 −𝑠/𝜏
𝑠𝜏 𝑠

Equation 5.5

5.3.7 Particle Tracking
The external forces (shear, torque, van der Waals, repulsion) as described in the
previous section are functions of the position of the polymersome within the deterministic
lateral displacement grid. Once these external forces are calculated for the interaction
between the polymersome and each post, we sum over all of the posts to calculate the
net external forces. The polymersome trajectory can be calculated using the
hydrodynamic mobility function. A linear relationship describes the velocity of the particle
to the external forces,

̿ )(𝒰̅)
(ℱ̅ ) = −𝜇(𝓡

Equation 5.6

1
−1
̿ ) (ℱ̅ )
(𝒰̅) = − (𝓡
𝜇

Equation 5.7

̿̿̿̿), is the inverse of the resistance matrix, (𝓡
̿ ), and relates
The mobility matrix, (𝓜
the applied external forces to the polymersome linear and angular velocity. The
̿ ) are given in the Appendix and are described in detail by Brenner [15].
coefficients of (𝓡
Brenner suggested that in the absence of a center of hydrodynamic stress, the
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hydrodynamic resistance of a particle could be expressed in terms of three second-rank
tensors, termed the Translation Tensor, the Rotational Tensor, and the Coupling Tensor
[15]. These three tensors comprise the resistance matrix. Equation 5.7 implies that the
inertial forces have been neglected, which is true in our case since the polymersomes
have negligible mass, and that the fluid responds instantly to the changes in particle
motion.

Polymersome trajectories are calculated as follows. At every time step, the
position of the polymersome is known within the grid. Based on the position we can
calculate all of the forces exerted on the polymersome. As detailed in the Appendix, the
Coupling Tensor is proportional to 1/ℎ4, and for this reason we calculate the resistance
matrix for the polymersome-post pair that has the shortest center-to-center distance.
̿ ) and (ℱ̅ ) are known, Equation 5.7 can be solved for the particle linear and
Once (𝓡
angular velocity. The polymersome position is updated based on the linear velocity, and
the trajectory calculation is repeated at the next time step. The schematic of the
geometry in the computational model is shown in Figure 5-1.
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Figure 5-1: Top-view geometry of computational model. A polymersome of radius 𝒂 interacts with a
periodic array of cylindrical posts of radius 𝑹. The array is rotated by angle 𝜽′ with post edge-to-edge
̅ and angular velocity 𝝎
̅.
distance 𝝀. The polymersome moves with linear velocity 𝑽

5.4 Results
5.4.1 Two-Body Simulation: Polymersome and Post
We first studied the simplest case of a polymersome interacting with a single
post. We use this example to illustrate the importance of the Hamaker constant (𝐻) and
polymer chain compressibility (𝛾) in the model. The interplay between attraction and
repulsion is important as it will dictate the particle trajectory and ultimately the separation
of the polymersome within the DLD grid. We began by placing the particle far away from
the post and introducing a fluid flow in the positive x-direction. Depending on the yposition of the polymersome relative to the post, the polymersome will either clear the
post completely following its unperturbed hydrodynamic trajectory, or the will come into
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close proximity with the post and experience a combination of attraction and repulsion
perturbing its hydrodynamic trajectory. We can derive an expression for the critical yposition where the initial incident y-position is equal to the final y-position after
encountering the post,

𝑦𝐻𝑦𝑑 = 𝑎 + 𝑅𝑝 −

𝑅𝑝2
𝑎 + 𝑅𝑝

Equation 5.8

In the case where the particle’s trajectory is unperturbed by the post, 𝑦𝑖𝑛 ≥ 𝑦𝐻𝑦𝑑 and the
final y-position is equal to the initial position, 𝑦𝑜𝑢𝑡 = 𝑦𝑖𝑛 . In the case where the
polymersome can feel the post’s presence, 𝑦𝑖𝑛 < 𝑦𝐻𝑦𝑑 and 𝑦𝑜𝑢𝑡 = 𝑦𝐻𝑦𝑑 . Values of the
Hamaker constant and polymer chain compressibility affect 𝑦𝑜𝑢𝑡 in the latter case when
the polymersome can “feel” the post.
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Figure 5-2: Single Polymersome-Post Interaction. a) Representative polymersome trajectory (motion of
centers) with 𝑹⁄𝒂 = 𝟐 for fixed 𝜸 = 𝟏𝟎−𝟕 𝑵. Values of the Hamaker constant are 𝟏 × 𝟏𝟎−𝟏𝟒 𝑱 (solid line),
𝟑 × 𝟏𝟎−𝟏𝟒 𝑱 (long dash), and 𝟓 × 𝟏𝟎−𝟏𝟒 𝑱 (short dash). b) Deviation from hydrodynamic trajectories as a
function of varying Hamaker constant. 𝜸 = 𝟏𝟎−𝟕 𝑵. c) Deviation from hydrodynamic trajectories as a function
of varying and polymer chain compressibility. 𝑯 = 𝟑. 𝟕 × 𝟏𝟎−𝟏𝟒 𝑱.

Figure 5-2 illustrates the effects of varying the Hamaker constant and polymer chain
compressibility on polymersome trajectory of different post to polymersome size (𝑅/𝑎)
ratios. Figure 5-2a shows a representative trajectory of a polymersome at 𝑅⁄𝑎 = 2. We
see that increasing the Hamaker constant causes the polymersome to have a greater
contact time with the post and have a lower 𝑦𝑜𝑢𝑡 . We can represent deviations from the
unperturbed hydrodynamic trajectory by normalizing 𝑦𝑜𝑢𝑡 with 𝑦𝐻𝑦𝑑 , where a ratio of one
implies a completely hydrodynamic interaction and values less than one indicate the
relative strength of non-hydrodynamic interactions (i.e. attraction and repulsion). Figure
5-2b and Figure 5-2c show the deviations from the unperturbed hydrodynamic trajectory
as a function of varying the Hamaker constant and polymer chain compressibility. For all
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size ratios, increasing the attraction increased the contact time between the
polymersome and post, whereas increasing the repulsion decreased the contact time.
The polymersome trajectory is more sensitive to variations in the Hamaker constant than
variations in the polymer chain compressibility, and smaller polymersomes are even
more sensitive to this change. For the case of 𝑅⁄𝑎 = 2, increasing 𝐻 by a factor of five
increased the perturbation from the hydrodynamic trajectory by 30%, whereas increasing
𝛾 by a factor of 100 reduced the perturbation by 14%. We also found that a Hamaker
constant of 5 × 10−14 𝐽 imposed a very strong attraction between the polymersome and
the post for 𝑅⁄𝑎 = 3 such that the polymersome trajectory wrapped around the post.
This result is physically unattainable in the experimental system and helped establish
upper limits for values of the Hamaker constant.

Since the trajectories are not very sensitive to changes in the polymer chain
compressibility, we calculated the attractive and repulsive forces felt by the
polymersome due to a single post for varying Hamaker constants at a constant 𝛾 (Figure
5-3). Figure 5-3a and Figure 5-3b show the attractive and repulsive force, respectively,
during the polymersome-post contact. Both forces are zero before and after the contact
period. Figure 5-3c and Figure 5-3d show the maximum force felt by the polymersomes,
which occurred at initial point of contact between the polymersome and post.
Interestingly, we found that the repulsive force depends exponentially on 𝐻 . By
monotonically increasing the Hamaker constant, we are exponentially increasing the
repulsion experienced by the polymersome.
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Figure 5-3: Attractive and repulsive forces during interaction. a) Repulsive force and b) attractive force
felt by the polymersome for 𝑹⁄𝒂 = 𝟐, 𝜸 = 𝟏𝟎−𝟕 𝑵, and 𝑯 = 𝟎 𝑱 (black), 𝟏 × 𝟏𝟎−𝟏𝟒 𝑱 (red), 𝟐 × 𝟏𝟎−𝟏𝟒 𝑱 (green),
𝟑 × 𝟏𝟎−𝟏𝟒 𝑱 (blue), 𝟒 × 𝟏𝟎−𝟏𝟒 𝑱 (pink), 𝟓 × 𝟏𝟎−𝟏𝟒 𝑱 (cyan). The arrow in (a) shows a dip in the forces and is
indicative of the point where the polymersome breaks contact with the post. (c) Maximum repulsive force. (d)
Maximum attractive force. The force vectors point radially outward, starting at the post center and ending at
the polymersome center.

5.4.2 Determination of Computational Grid Size
The forces exerted on the polymersomes are a numerical sum of individual post
contributions. While we can generate a post array of an arbitrary size and rotation, it is
unnecessary to include force contributions from all posts. The hydrodynamic, repulsive,
and attractive forces and the hydrodynamic torque are inverse power law functions of ℎ.
As a result, posts that are far away from the polymersome will have negligible
contributions to the net calculated force. Figure 5-4 shows the cumulative sum of the
non-dimensional forces and torque as a function of the number of nearest posts that are
included in the summation.
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Figure 5-4: Cumulative sum of non-dimensional forces and torque on polymersome. A polymersome
(a = 25 µm) was placed in the center of an array of posts with R = 50 µm, λ = 60 µm, θ = 8º. The calculated
forces and torque are cumulative sums from post contributions, starting with the nearest post and working
radially outward. The red dash represents the “equilibrium” value, which is the cumulative sum from all
posts.

As can be seen from Figure 5-4, the equilibrium force or torque value is reached after
summation of a finite number of posts. The grid used to calculate the forces and torque
contained a total of 7177 posts. The oscillatory behavior in the hydrodynamic forces (𝐹𝑥
and 𝐹𝑦 ) are severely damped after summing over 100 nearest posts, indicating that (to a
good approximation) the equilibrium value has been reached. The hydrodynamic torque
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requires even fewer nearest posts (10) to reach equilibrium. The repulsive force is
shown to be zero for all post numbers because the polymersome is not in physical
contact with the post. This behavior suggests that the repulsive force contribution is a
very short range interaction, and only comes from the single nearest post when the
polymersome is on the order of 𝜏 µm away from the post. Similarly, the attractive force is
also a short range interaction, with the polymersome feeling the presence of the nearest
two posts. We can conclude from this study that it is unnecessary to include force and
torque contributions from all posts within a microfluidic device. The power of this
technique implies that one can study the separation of polymersomes within an
extremely large grid size simply by calculating the force contributions from the nearest 𝑛
neighbors.

5.4.3 Experimental Results
The microfluidic device contained three sections: inlet section, fractionation
section, and collection section (Figure 5-5). The inlet section consisted of three inlets.
The left and right inlets maintained the laminar flow throughout the device, while the
center inlet introduced the polymersomes into the device. The fractionation section
contained an array of cylindrical posts 100 µm in diameter with an edge-to-edge post
spacing of 60 µm and grid rotation of 8º. The size-based separation of polymersomes
occurred in this section. The collection section consisted of five outlets. The separated
polymersomes exited the device via the outlets.
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Figure 5-5: Microfluidic device schematic. The device contains three distinct regions: inlet, fractionation,
and outlet. The polymersomes were introduced into the device through the center inlet channel. The left and
right inlet channels helped maintain the fluid laminarity throughout the rest of the device. The fractionation
channel contained an array of cylindrical posts with an edge-to-edge distance of 60 µm and post diameter of
100 µm. The overall grid rotation was 8º. The outlet channels were used to collect fractionated
polymersomes. It should be noted that the separation occurred in the left half of the device due to the grid
rotation.

Based on the grid rotation, the separation occurred in the left half of the device. Two
sizes of polymersomes (46 and 58 µm) were separately introduced into the microfluidic
device and the vesicle trajectories are shown in Figure 5-6. The 58 µm polymersomes
followed the 8º path mapped out by the grid rotation and did not deviate from this path
(Figure 5-6B). The 46 µm polymersomes were seen to deviate from the 8º path and
cross over into different lanes (Figure 5-6A).
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Figure 5-6: Polymersome trajectories in a 400 µm x 1600 µm region in the fractionation zone of the
microfluidic device. a) Trajectories of 46 µm polymersomes. Scale bar = 200 µm. b) Corrected trajectories
of 46 µm polymersomes, adjusted to start at the same point. c) Corrected trajectories of 58 µm
polymersomes, adjusted to start at the same point.

We calculated the average migration angle of the polymersomes within this region and
found that there is a 4º separation between the 46 and 58 µm polymersomes (Figure
5-7). This translated to the polymersomes being separated and collected in different
collection lanes.
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Figure 5-7: Polymersome trajectories within microfluidic device. a) Average migration angle of the two
polymersomes as determined from experiment. Error bars indicate standard error or the mean. N = 12 for 46
µm polymersomes and N = 11 for 58 µm polymersomes. b) Visualization of the endpoint of migration within
the device based on the average migration angle. The shaded region indicates the range of migration as
determined from the standard error.

Using the Hamaker constant and polymer brush compressibility parameters
established previously, we can use the model to predict the separation of 46 and 58 µm
polymersomes (Figure 5-8).

Figure 5-8: Predicting polymersome fractionation. a) 46 µm polymersomes and b) 58 µm polymersomes
fractionated in a DLD device. Dashed lines represent computational simulations and solid lines represent
actual experiments.
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5.5 Conclusion
We developed a hydrodynamic, forced-based computational model to understand
the fractionation of polymersomes in a DLD microfluidic device. We found that the key
parameter in determining the separation between two particles is primarily determined
by the strength of the attraction between the cylindrical post and spherical polymersome.
Interestingly, we found that the repulsive force experienced by the polymersome
depends exponentially on 𝐻. Using this model, we can correctly predict the fractionation
of two polymersomes of different sizes (46 and 58 µm) in a DLD device.
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5.7 Appendix
5.7.1 Fluid Velocity within the Microfluidic Device
The Reynolds number for the steady motion of a sphere with velocity 𝑉 and
diameter 𝐷𝑝 moving through a fluid with density 𝜌 and viscosity 𝜇 is

ReD =

𝜌𝑉𝐷𝑝
𝜇

Equation 5.9

For our present system, ReD ≪ 1 and we can reduce the full Navier-Stokes equation to
the Stokes equation,

∇𝑃 = 𝜇∇2 𝑣

Equation 5.10

and determine the velocity throughout the microfluidic device. Consider first the simple
case of fluid flow past one cylinder. We can analytically determine the fluid velocity past
this cylinder by invoking streamline solutions of known problems and the principle of
superposition. The fluid velocity past a cylinder is a superposition of a uniform fluid
velocity and a doublet flow as shown in Figure 5-9.
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Figure 5-9: Streamlines solutions for velocity fields. a) Uniform 1D flow. b) Doublet flow. c)
Superposition of (a) and (b) resulting in the solution for the non-lifting flow past a cylinder.

The streamlines for the velocity fields presented in Figure 5-9 are given by

𝜓𝑢𝑛𝑖𝑓𝑜𝑟𝑚 = 𝑈𝑦

𝜓𝑑𝑜𝑢𝑏𝑙𝑒𝑡 = −

𝜅 sin 𝜃
2𝜋 𝑟

Equation 5.11

Equation 5.12

Transforming Equation 5.11 into polar coordinates (or conversely Equation 5.12 into
rectangular coordinates) and invoking superposition, the streamlines for Figure 5-9c are
given by

𝑅2
Ψ = 𝑈𝑟 sin 𝜃 (1 − 2 )
𝑟
Equation 5.13

Ψ = 𝑈𝑦 (1 −

𝑅2
)
𝑥2 + 𝑦2

where the substitution 𝜅⁄2𝜋𝑈 = 𝑅 2 has been made. The velocity components can be
calculated from the streamlines by taking the appropriate partial derivatives
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𝑣𝑥 =

∂Ψ
𝑥2 − 𝑦2
= 𝑈 − 𝑈𝑅 2 2
(𝑥 + 𝑦 2 )2
𝜕𝑦

Equation 5.14

∂Ψ
𝑥𝑦
= −2𝑈𝑅 2 2
(𝑥 + 𝑦 2 )2
𝜕𝑥

Equation 5.15

𝑣𝑦 = −

Translating this solution to the problem of 𝑛 cylindrical posts in our microfluidic device,
we can once again invoke superposition and sum over the 𝑛 posts
𝑛
2

𝑣𝑥 = 𝑈 − 𝑈𝑅 ∑
𝑖=1

𝑛
2

𝑣𝑦 = −2𝑈𝑅 ∑
𝑖=1

(𝑥 − 𝑥𝑖 )2 − (𝑦 − 𝑦𝑖 )2
[(𝑥 − 𝑥𝑖 )2 + (𝑦 − 𝑦𝑖 )2 ]2

(𝑥 − 𝑥𝑖 )(𝑦 − 𝑦𝑖 )
[(𝑥 − 𝑥𝑖 )2 + (𝑦 − 𝑦𝑖 )2 ]2

Equation 5.16

Equation 5.17

where (𝑥𝑖 , 𝑦𝑖 ) refer to the coordinates of the cylindrical posts. We can see from Equation
5.16 and Equation 5.17 that the x- and y-velocity components depend on all of the posts.
The 1⁄𝑟 4 dependence, however, implies that far away posts have less of a contribution
to the velocity at a given point than posts that are closer.

5.7.2 Torque on the Polymersome
Consider once again the solution to the problem of fluid flow past one cylinder.
The rectangular velocities presented in Equation 5.14 and Equation 5.15 can be
converted to cylindrical velocities and are given by:
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𝑣𝑟 = 𝑈 cos 𝜃 (1 −

𝑅2
)
𝑟2

𝑣𝜃 = −𝑈 sin 𝜃 (1 +

𝑅2
)
𝑟2

Equation 5.18

Equation 5.19

In order to calculate the torque on the polymersome due to the fluid, we must first
determine the fluid viscous stress, which can be determined by taking the appropriate
partial derivative of the fluid velocity:

𝜏𝑟𝜃 = 𝜇 [𝑟

𝜕 𝑉𝜃
1 𝜕𝑉𝑟
4𝜇𝑈𝑅 2 sin 𝜃
( )+
]=
𝜕𝑟 𝑟
𝑟 𝜕𝜃
𝑟3

Equation 5.20

The torque on the polymersome can be calculated by integrating the viscous stress over
the surface of the particle. Every point on the surface of the polymersome can be
parameterized with a position vector 𝑟⃑ as show in Figure 5-10.

𝑟⃑ = (𝑎 sin 𝜙 cos 𝜃 + 𝑝)𝑖̂ + (𝑎 sin 𝜙 sin 𝜃 + 𝑞)𝑗̂ + 𝑎 cos 𝜙 𝑘̂
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Equation 5.21

Figure 5-10: Post and polymersome geometry. Top view of cylindrical post located at the origin O with
coordinates (0,0,0) and spherical polymersome located at P with coordinates (p,q,0).

For the purposes of the torque calculation, we will assume that the top and bottom
edges of the post do not affect the polymersome and as such the z-direction in the
parameterization is neglected. The viscous stress can be restated in terms of the
parameterization as follows:

𝜏𝑟𝜃 = 4𝜇𝑈𝑅 2

|𝑟⃑𝑥𝑦 ∙ 𝑗̂|
|𝑟⃑𝑥𝑦 |

∙

1
3

|𝑟⃑𝑥𝑦 |

Equation 5.22

The expression for the differential torque on the polymersome is given by:

𝑑𝐺 = 𝜏𝑟𝜃 ∙ 𝑎 sin 𝜙 𝑑𝑆

Equation 5.23

and the differential surface element on the polymersomes is:

𝑑𝑆 = 𝑎2 sin 𝜙 𝑑𝜙𝑑𝜃
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Equation 5.24

The final expression for the torque on the polymersome can be determined by combining
Equation 5.22 – Equation 5.24:

𝐺
2𝜋 𝜋
2 3

= 4𝜇𝑈𝑅 𝑎 ∫ ∫
0

0

𝑎 sin 𝜙 sin 𝜃 + 𝑞
sin2 𝜙 𝑑𝜙𝑑𝜃
[(𝑎 sin 𝜙 cos 𝜃 + 𝑝)2 + (𝑎 sin 𝜙 sin 𝜃 + 𝑞)2 ]2

Equation 5.25

This integral was evaluated numerically using MATLAB.

5.7.3 The Grand Mobility Matrix
The resistance matrix (Equation 5.6) can be re-written to show all of the
individual components as follows:

𝐹𝑥
𝑉𝑥
𝐹𝑦
𝑉𝑦
𝐹𝑧
𝑲 𝑫 𝑉𝑧
= −𝜇 [
]
𝑇𝑥
𝑪 𝛀 𝜔𝑥
𝜔𝑦
𝑇𝑦
[
𝜔𝑧 ]
[ 𝑇𝑧 ]

Equation 5.26

where 𝐹𝑖 is the external force acting on the polymersome, 𝑇𝑖 is the external torque acting
on the polymersome, 𝑉𝑖 is the polymersome linear velocity, and 𝜔𝑖 is the polymersome
angular velocity in the 𝑥, 𝑦, and 𝑧 directions. The four components of the resistance
matrix consist of the translational dyadic (𝑲), the rotational dyadic (𝛀), and the coupling
dyadic (𝑪), and the transpose of the coupling dyadic (𝑫). The resistance matrix for a
sphere-cylinder system can be approximated by considering a sphere-sphere system.
Detailed analysis of this system is presented by Brenner [15]. Let spheres 1 and 2 have
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radii 𝑎1 and 𝑎2 , respectively. Let the instantaneous center-to-center distance be 2ℎ and
let 𝑒̂21 = −𝑒̂12 be a unit vector drawn from the center of sphere 2 to sphere 1. The
sphere-sphere system can be described by the following system of equations:

⃑⃑1 + 𝑲𝟏𝟐 ∙ 𝑈
⃑⃑2 + 𝑫𝟏𝟏 ∙ 𝜔
𝐹⃑1 = −𝜇(𝑲𝟏𝟏 ∙ 𝑈
⃑⃑1 + 𝑫𝟏𝟐 ∙ 𝜔
⃑⃑2 )
⃑⃑1 + 𝑲𝟐𝟐 ∙ 𝑈
⃑⃑2 + 𝑫𝟐𝟏 ∙ 𝜔
𝐹⃑2 = −𝜇(𝑲𝟐𝟏 ∙ 𝑈
⃑⃑1 + 𝑫𝟐𝟐 ∙ 𝜔
⃑⃑2 )
Equation 5.27

⃑⃑1 = −𝜇(𝑪𝟏𝟏 ∙ 𝑈
⃑⃑1 + 𝑪𝟏𝟐 ∙ 𝑈
⃑⃑2 + 𝛀𝟏𝟏 ∙ 𝜔
𝑇
⃑⃑1 + 𝛀𝟏𝟐 ∙ 𝜔
⃑⃑2 )
⃑⃑2 = −𝜇(𝑪𝟐𝟏 ∙ 𝑈
⃑⃑1 + 𝑪𝟐𝟐 ∙ 𝑈
⃑⃑2 + 𝛀𝟐𝟏 ∙ 𝜔
𝑇
⃑⃑1 + 𝛀𝟐𝟐 ∙ 𝜔
⃑⃑2 )

⃑⃑2 = 𝜔
In our simulation, sphere 2 will be held motionless and 𝑈
⃑⃑2 = 0. For sphere 1,
Equation 5.27 reduces to:

⃑⃑1 + 𝑫𝟏𝟏 ∙ 𝜔
𝐹⃑1 = −𝜇(𝑲𝟏𝟏 ∙ 𝑈
⃑⃑1 )
Equation 5.28

⃑⃑1 = −𝜇(𝑪𝟏𝟏 ∙ 𝑈
⃑⃑1 + 𝛀𝟏𝟏 ∙ 𝜔
𝑇
⃑⃑1 )

Due to the interaction between the spheres, the four dyadic take the form of

𝑲𝟏𝟏 = 6𝜋𝑎1 [𝑰 +

9 𝑎1 𝑎2
( ) ( ) (𝑰 + 3𝑒̂12 𝑒̂12 )]
64 ℎ
ℎ

𝛀𝟏𝟏 = 8𝜋𝑎13 [𝑰 +

3 𝑎1 3 𝑎2
( ) ( ) (𝑰 − 𝑒̂12 𝑒̂12 )]
64 ℎ
ℎ
Equation 5.29

𝑪𝟏𝟏

9
𝑎1 3
=
𝜋𝑎1 𝑎2 ( ) [𝑒̂12 × 𝑰]
16
ℎ

𝑫𝟏𝟏 = −

9
𝑎1 3
𝜋𝑎1 𝑎2 ( ) [𝑰 × 𝑒̂12 ]
16
ℎ
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where 𝑰 is the identity dyadic. If we define the center of the polymersome at (p,q) and the
center of the post at (0,0), we can express the entire cross and dyadic products with the
unit vector 𝑒̂12 in Equation 5.29 as follows:

𝑒̂12 = −

𝑒̂12 𝑒̂12

𝑝
𝑞
𝑖̂ −
𝑗̂
2ℎ
2ℎ

2
1 𝑝
= 2 [𝑝𝑞
4ℎ
0

𝑝𝑞
𝑞2
0

𝑒̂12 × 𝑰 = 𝑰 × 𝑒̂12 =

0
0]
0

1 0
[0
2ℎ 𝑞

Equation 5.30

0 −𝑞
0
𝑝]
−𝑝 0

Finally, substituting Equation 5.30 into Equation 5.29 we obtain the final expression for
the components of the resistance matrix:

𝑲𝟏𝟏

1 0
= 6𝜋𝑎1 [0 1
0 0
1

𝛀𝟏𝟏 =

8𝜋𝑎13 [0
0

𝑪𝟏𝟏 =

𝑫𝟏𝟏

2
0
9 𝑎1 𝑎2 1 + 3𝑝
0] + ( ) ( ) [ 3𝑝𝑞
64 ℎ
ℎ
1
0

2
0 0
3 𝑎1 3 𝑎2 1 − 𝑝
1 0] + ( ) ( ) [ −𝑝𝑞
64 ℎ
ℎ
0 1
0

9
𝑎1 3 1 0
𝜋𝑎1 𝑎2 ( )
[0
16
ℎ 2ℎ 𝑞

9
𝑎1 3 1 0
=
𝜋𝑎 𝑎 ( )
[0
16 1 2 ℎ 2ℎ −𝑞

0
0
−𝑝

−𝑞
𝑝]
0

0
0
𝑝

𝑞
−𝑝]
0
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3𝑝𝑞
1 + 3𝑞 2
0
−𝑝𝑞
1 − 𝑞2
0

0
0]
1
0
0]
1

Equation 5.31

The grand mobility matrix can now be determined by inverting the resistance matrix:

̿ = [𝑲𝟏𝟏
ℳ
𝑪𝟏𝟏
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𝑫𝟏𝟏 −1
]
𝛀𝟏𝟏

Equation 5.32
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6 Summary of Major Results and
Suggested Future Research
6.1 Major Results with Respect to the Specific Aims

Aim 1:

Develop controlled release nano-polymersome platform for the encapsulation
and release of chemotherapeutic drug and determine toxicity in cancer cells.

Results: A nano-polymersome system using a biodegradable and biocompatible block
copolymer, PEO-PCL, was developed to encapsulate the chemotherapeutic
drug gemcitabine, and released this cargo based on an external pH stimulus
(acidic environment). We determined the efficacy of the PolyGems compared
to the unencapsulated drug, FreeGem, and found that the PolyGems
performed at par with the free drug with a total cell killing of 1 log at 1 µM
gemcitabine dose.
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Aim 2:

Quantify the release of an encapsulated fluorescent dye from giant
polymersomes due to photo-initiated rupture.

Result: The rupture of giant polymersomes made from OB14.5 and OB29 polymers
was quantified by detecting the released fraction of a fluorescent dye,
sulforhodamine B, from the aqueous core of the vesicles. Polymersomes were
irradiated using a 690 nm diode laser with a fluence rate of 200 mW/cm 2 and a
maximal light dose of 100 J/cm2. OB14.5 polymersomes released more
sulforhodamine B than OB29 polymersomes because OB14.5 polymersomes
have a softer membrane.
Aim 3:

Encapsulate a photosensitizer in nano-polymersomes for photodynamic
therapy and assess the in vitro and in vivo toxicity of the polymersomes.

Result: A second generation photosensitizer, benzoporphyrin derivative monoacid A
(BPD-MA), was encapsulated in the hydrophobic membrane of OB14.5 nanopolymersomes at a high molar loading ratio (40%). We compared the in vitro
and in vivo toxicity of OB14.5-40% BPD to a liposomal formulation of BPD-MA,
verteporfin. OB14.5-40% BPD polymersomes outperformed verteporfin both in
in vitro toxicity assays and in vivo tumor response. The polymersomes serve to
protect BPD-MA from being leached by serum proteins, and as such the
concentration of BPD-MA that is unbound and able to generate singlet oxygen
is greater than when verteporfin is used as the carrier vehicle.
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Aim 4:

Develop a force-based model for understanding and predicting polymersome
fractionation in a deterministic lateral displacement microfluidic device.

Results: A hydrodynamic model was developed that incorporated shear, hydrodynamic
torque, van der Waals attraction, steric repulsion as the forces and torques felt
by the polymersome as it navigates a deterministic lateral displacement device.
We found that the most sensitive parameter in fractionating the polymersomes
is the Hamaker constant, which dictated the length of the “contact time”
between the polymersome and the cylindrical post. We conducted experiments
that fractionated polymersomes of two different sizes, and recapitulated this
experimental result via a numerical simulation using the model that was
developed.

6.2 Further Investigations Towards the Development of Dual Drug
Delivery Polymersomes

for

Combined Chemotherapy and

Photodynamic Therapy
The systemic toxicities associated with chemotherapy suggest that there is a
strong need to provide local delivery of drugs to tumors. The work presented in Chapters
2 and 4 of this dissertation outline two strategies for encapsulating chemotherapeutics
and photosensitizers for PDT, respectively. Combining these modalities can have a
synergistic effect on treatment outcomes.

Several challenges must be considered for a dual-delivery system to be
successful. An important question to answer consider is which therapy to do first –
chemotherapy with polymersomes requires diffusion of the drug out of the aqueous
lumen and into the tumor and PDT requires photosensitizer accumulation followed by
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irradiation of the diseased tissue. One can allow for the drug to escape the
polymersomes and cause cell damage, and then irradiate with light to generate singlet
oxygen. However, the time scale for release of the chemotherapeutic drug might not
match the time scale for accumulation of the photosensitizer, i.e. the drug is being
released into the tumor while the photosensitizer is being cleared from the tumor.

An alternate strategy would be to do PDT first with a short drug-light interval and
cause vascular damage surrounding the tumor [1]. The tumor will lose its nutrient supply
and undergo cell death. While this vascular shutdown is taking place, the
chemotherapeutic can diffuse out of the polymersomes and cause direct cell death.

The polymersome drug delivery system can be improved by adding targeting
ligands onto the surface of the polymersome. The overexpression of EGFR on OVCAR5 cells can be exploited to preferentially accumulate polymersomes at the tumor site as
opposed to other tissues. Work has been previously done conjugating cetuximab to
BPD-MA, but this photoimmunoconjugate was not effective at killing OVCAR-5 cells [2].
It is possible that cetuximab hindered the ability of BPD-MA to effectively generate
singlet oxygen. A polymersome system could be an improvement over the direct
conjugation of an antibody to BPD-MA. The surface of polymersomes can be conjugated
via peptide coupling reactions to include EGF binding domains (RGD domain). A newer
approach would be to blend short surfactant-like peptides containing the binding domain
with the polymer. Our lab developed has a family of oleosin mutants that resemble block
copolymers [3]. Using molecular biology, one could include the RGD binding domain on
the terminal end of the peptide and blend this targeting peptide with the polymer.
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